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GENERAL iNTRODUCTiON
Adapted from two reviews:
Wang Y, van der Zee M, fodde R, et al. Wnt/Beta-catenin and sex hormone 
signaling in endometrial homeostasis and cancer. Oncotarget. 2010;1:674-684.
van der horst Ph, Wang Y, van der Zee M, et al. interaction between 
sexhormones and WNT/beta-catenin signal transduction in endometrial 
physiology and disease. Mol Cell Endocrinol. 2011 in press
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1.1 DEvELOPMENT Of ThE fEMALE REPRODUCTivE TRACT
Wolffian (mesonephric) and Müllerian (paramesonephric) ducts are the developmental 
precursors of a major part of the male and female genital tracts, exclusive of the 
external genitalia and the gonads. During early mouse embryogenesis, Wolffian ducts 
are formed at embryonic day 9 (E9) from the intermediate mesoderm, and Müllerian 
ducts start to form around E11.5 from the coelomic epithelium1-2 (fig. 1). This occurs 
in embryos of both sexes. in female mouse embryos, in the coelomic epithelium, 
Lim1 expressing cells are induced to invaginate by Wnt4, which is expressed from 
the nearby Wolffian duct or from surrounding coelomic epithelial cells3 (fig. 1A and 
B).  The transcription factor Lim1 is an essential regulator in development, and Lim1 
knockout mice lack anterior head formation4. furthermore, Lim1 knockout female mice 
lack a uterus and oviducts. Subsequently, invaginating cells start to proliferate and the 
structure elongates along the Wolffian duct. This elongation of the Müllerian ducts is 
mediated by Wnt9b expressing epithelial cells from the Wolffian duct5 (fig. 1C). Either 
in the absence of Wolffian ducts or in the absence of Wnt9b, the Müllerian ducts do not 
develop further. Outgrowth of the Müllerian duct is accomplished by proliferation of 
a group of coelomic epithelial cells resembling mesoepithelial cells at the distal tip6-7. 
At the end of elongation, both Müllerian ducts will fuse to form the uterovaginal tube, 
which joins the urogenital sinus thus starting to shape the upper part of the vagina. 
Between E11.5 and E13.5, both Wolffian and Müllerian ducts preexist in the same 
embryo regardless of its genetic sex (fig. 1D). After E13.5, however, the destiny of 
Wolffian and Müllerian ducts becomes determined by hormones secreted from the 
gonads8-9. in male sexual development, anti-Müllerian hormone (AMh) secreted by 
Sertoli cells in the testes binds to the AMh receptor (AMhR) on mesenchymal cells 
surrounding the Müllerian ducts10, which results in apoptosis of the Müllerian ducts, 
while Wolffian ducts are stabilized and further develop (to become epididymis, vas 
deferens, seminal vesicle) under the influence of testosterone (fig. 1f). in female sexual 
development, when there is no production of AMh by the fetal gonads, Müllerian ducts 
develop into the female reproductive tract. At the same time Wolffian ducts regress 
due to lack of testosterone11  (fig. 1E). Once initiated, correct patterning of the Müllerian 
ducts into upper part of the vagina, and the cervix, uterus and oviducts partly depends 
on epithelial cells of the oviduct and uterus expressing Wnt7a, and mesenchymal cells 
of the uterus, cervix and vagina expressing Wnt5a12-13. from the above, it is evident that 
there is a strong relationship between Wnt signaling and Müllerian duct development. 
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Figure 1. Schematic overview of female reproductive tract development during embryogenesis. Müllerian 
duct formation (A-C), Wolffian and Müllerian ducts coexist (D), Wolffian duct regression (E), Müllerian duct 
regression (f). Adapted from Kobayashi and Behringer, 2003.
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1.2 ADULT UTERiNE PhYSiOLOGY
The female internal reproductive system contains four main parts: the ovaries, oviducts, 
uterus and vagina (fig. 2, left: human; right: mouse). The four parts connect to each 
other and have different functions. The ovaries produce ova and secrete hormones to 
regulate female physiology. The oviducts, also known as fallopian tubes, are two tubes 
linking the ovaries and the uterus. in mice, oviducts are connected to the ovaries by 
a bursal pouch, which is not present in human. The oviducts are the place where the 
ovum normally gets fertilized. The uterus is the biggest female internal reproductive 
organ and it is designed to feed and protect the developing embryo. The vagina is the 
tract between the uterus and the exterior of the body. it functions as a receptacle for 
the male’s sperm during coitus, a passage for menstrual tissue and blood, and as the 
birth canal.
Figure 2. Schematic representation of the human (left) and mouse (right) female reproductive tract. The 
murine uterus has two horns and the ovaries are covered by bursae.
The inner layer of the human uterus, the endometrium is a dynamic tissue that 
undergoes hundreds of cycles of proliferation, differentiation and shedding during 
a woman’s reproductive years14. The human endometrium can be divided into two 
layers, the functionalis and the basalis. Whereas the functionalis layer comprises the 
upper two-thirds of the endometrium and is shedded during menstruation, the basalis 
includes the lower one-third which remains intact and is responsible for producing a 
new functionalis during each subsequent menstrual cycle14-15. 
it is the fine balance between the activities of the two female sex hormones, estradiol 
and progesterone, which determines lineage faith in the endometrium (fig. 3A). 
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During the first two weeks of the human menstrual cycle, thecal cells of the ovary 
produce large amounts of estradiol. Simultaneously the endometrial estrogen receptor 
(ER) expression level (mainly ERα) is increased16. Upon ligand binding, ER dimers will 
translocate to the nucleus where they activate transcription of downstream target 
genes (e.g. insulin-like growth factor; IGF1), that stimulate endometrial proliferation17. 
Later, during the third and fourth week of the menstrual cycle, the corpus luteum 
starts producing progesterone thus inhibiting estradiol-induced proliferation of 
endometrial cells and stimulating cellular differentiation18-19. if no fertilized oocytes are 
implanted in the uterus, the corpus luteum cannot be maintained due to lack of human 
chorionic gonadotropin (hCG), and both estrogen and progesterone levels will decline. 
Withdrawal of progesterone leads to endometrial cell apoptosis and tissue breakdown 
of the functionalis of the endometrium, resulting in its shedding from the uterus 20. 
Figure 3. hormonal (A) and morphological (B) changes during the normal menstrual/estrous cycle in human/
mouse and during endometrial oncogenesis (C). in case of enhanced or unopposed estrogen signaling, the 
endometrium may develop hyperplasia, which may eventually develop further into endometrial cancer. 
Changes in Wnt/β-catenin signalling in the endometrium are indicated at the bottom of the figure. Adapted 
from Wang et al. 2010.
1.3 WNT SiGNALLiNG AND iTS ROLE iN ADULT UTERiNE 
PhYSiOLOGY
Since the discovery of the proto-oncogene Wnt1 in 1982, the Wnt signalling pathway has 
been shown to be a key regulator in development, adult homeostasis, and disease 21-22. 
Currently, 20 secreted Wnt proteins have been identified among mammalian species 
that can bind to cell surface receptors of the frizzled family22. Upon binding, three 
different pathways can be activated: the canonical Wnt/ β-catenin signaling pathway22, 
the non-canonical Wnt/Planar cell polarity pathway23 or the Wnt/Ca2+ pathway23. 
Because in an early stage of our investigations progesterone inhibition of canonical 
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Wnt/β-catenin signaling was observed, in this thesis, we have focused on canonical 
Wnt/β-catenin signaling in the female reproductive tract. Central in canonical Wnt/β-
catenin signaling is the destruction complex, a multi-protein complex consisting of 
the scaffold proteins Axin1 and Axin2 (conductin), β-catenin (CTNNB1), the tumor 
suppressor APC (adenomatosis polyposis coli) and the Ser-Thr kinases CK1 (casein 
kinase i) and GSK3β (glycogen synthase kinase 3 beta)24. in the absence of Wnt ligands, 
formation of the destruction complex triggers Thr/Ser-phosphorylation of β-catenin 
by CK1 and GSK3β, and its subsequent ubiquitination and proteasomal degradation. 
Upon Wnt signaling, the formation of the destruction complex is inhibited thus leading 
to cytoplasmic accumulation of β-catenin and its nuclear translocation22. Once in 
the nucleus, β-catenin interacts with members of the TCf/LEf transcription factor 
family, thus regulating the expression of a broad spectrum of Wnt/β-catenin signaling 
downstream target genes22,25,26. The latter include genes encoding proteins with a 
central role in cell proliferation and survival such as cyclin D1 (CCND1) and MYC, in 
addition to roles in a broad spectrum of other cellular functions i.e. cellular migration 
(e.g. CD44), cell adhesion (CDH1), extracellular matrix (MMP7) and many others22,27.
The role of Wnt/β-catenin signaling in the regulation of tissue homeostasis has 
been extensively investigated for the mouse gut22,28. Along the mouse intestinal tract, 
stem cells are located at the bottom of the crypts of Lieberkuhn where they give rise 
to new stem cells and to proliferating progenitor cells (transient amplifying, TA, cells)29. 
These progenitor cells actively divide and produce new cells that are pushed up along 
the flank of the crypt towards the villus and eventually differentiate into Goblet cells, 
enteroendocrine cells and absorptive epithelial cells30. A somewhat similar process 
seems to take place in the endometrium, where estrogen receptor activation in the 
basalis stimulates endometrial cell proliferation during the first half of the menstrual/
estrous cycle, thus giving rise to the functionalis. in the 2nd half of the cycle, the corpus 
luteum will produce progesterone, which reduces estrogen-driven proliferation 
and induces differentiation of the functionalis thus preparing the endometrium for 
implantation of the fertilized oocyte (fig. 3B). 
Wnt/β-catenin signaling activity along the crypt-villus axis of the intestine follows 
a decreasing gradient from the stem cell and proliferative compartment to the more 
differentiated compartment31. in the endometrium, Wnt/β-catenin signaling has also 
been suggested to play a role in regulating proliferation and differentiation during the 
menstrual cycle. Nei et al. (1999)32 observed that, in the human endometrium, nuclear 
β-catenin was clearly enhanced during the proliferative phase of the menstrual cycle, 
while it was mostly found in the cytoplasm and at the cell membrane during the 
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secretory phase. Recently, it was also observed that estradiol induces stabilization of 
intracellular β-catenin in the endometrium, and, upon inhibition of Wnt signaling (by 
using adenoviral SFRP2), estradiol-induced proliferation was abolished33. in two other 
studies34-35 LiCl was applied to the drinking water of mice to inhibit GSK3β activity and 
thereby activate Wnt signaling. LiCl-treated animals were characterized by increased 
proliferation and hyperplasia of the endometrium, thus mimicking sustained estrogen 
signaling.  
in summary, during the menstrual cycle in human and the estrous cycle in mouse, 
Wnt/β-catenin signaling is important to maintain the balance between proliferation 
and differentiation. (fig. 3B)
1.4 iNvOLvEMENT Of hORMONE SiGNALiNG iN UTERiNE 
PAThOPhYSiOLOGY
Besides playing a role in regulation of the menstrual cycle, the sex hormones are also 
involved in uterine pathophysiology, exemplified in diseases such as endometriosis 
and endometrial cancer (fig. 3C). 
Endometriosis, a common and benign gynaecological disorder, is characterized by 
the presence of endometrial glandular and stromal tissue outside the uterine cavity 
(pelvic peritoneum, on the ovaries and in the rectovaginal septum) and is associated 
with pelvic pain and infertility. Endometriosis has been reported to be an estrogen-
dependent disease displaying reduced progesterone receptor levels and resistance to 
progesterone therapy36-38.
Endometrial cancer is one of the most common cancers of the female genital tract 39. 
it accounts each year for approximately 142.000 new cases diagnosed worldwide, and for 
42.000 deaths40-41. Endometrial cancer is the seventh most common malignant disorder 
and its incidence is expected to increase in the near future due to the increase in life 
span and obesity42. Based on epidemiology, conventional histopathology, and clinical 
behavior, endometrial carcinoma can be divided into two subtypes. Type i endometrial 
cancer, comprising approximately 85% of the total endometrial carcinoma burden 
among western societies, resembles normal endometrial hyperplasia in morphology 
and is associated with increased or unopposed estrogen signaling41. Type i endometrial 
cancer often shows mutations in the PTEN and in DNA mismatch repair genes (MLH1, 
MSH2, MSH6). Also, oncogenic mutations in KRAS and/or CTNNB1 (β-catenin), are 
recognized major alterations43-45. Type ii endometrial cancer occurs predominantly in 
older post-menopausal women, is not correlated to increased estrogen exposure, and 
is generally associated with a poorer prognosis. Type ii endometrial cancers often show 
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mutations in P53 and ERBB2 (her2/neu)41,44-45.
in western, industrialized countries, two large groups of women are at increased 
risk of developing endometrial cancer: (i) women with significant overweight42, and 
(ii) those receiving tamoxifen for breast cancer treatment46-47. Tamoxifen is a selective 
estrogen receptor modulator (SERM) acting as an antiestrogen in mammary tissue, but 
showing estrogenic activity in the endometrium47. Currently, it is estimated that up to 
40% of all endometrial cancers could be related to obesity42. Since the prevalence of 
obesity is increasing, the incidence of obesity-related endometrial cancer is also on 
the rise48. Additional risk factors for the development of endometrial cancer include: 
polycystic ovarian syndrome, skipping menstrual periods, being nulliparous, late 
menopause onset, and the use of unopposed estrogen as hormone substitution 
therapy49. hence, enhanced estrogen signaling for prolonged periods of time, also 
as the result of insufficient progesterone levels, represents the main risk factor in 
endometrial cancer. Progesterone antagonizes the proliferative activity of estrogen 
by inducing epithelial and stromal cell differentiation in the endometrium 50-51. in fact, 
although progesterone (in the form of medroxyprogesterone acetate (MPA)) can be 
used for the palliative treatment of well-advanced and recurrent endometrial cancer, 
this treatment has a modest response rate (15-25%)52. in contrast, when progesterone, 
is employed as a primary treatment (e.g. in pre-menopausal women suffering from 
well-differentiated endometrial cancer and determined to preserve fertility), response 
rates are considerably improved (up to 60% or more)53,54. 
1.5 WNT SiGNALLiNG iN UTERiNE PAThOPhYSiOLOGY
Gene mutations leading to constitutive activation of canonical Wnt signaling have 
been found in many different cancer types (e.g. breast, colon, stomach, liver, ovary, 
skin, etc). Also in the case of endometrial cancer, activation of Wnt/β-catenin signaling 
is likely to play an important role in early tumorigenesis43,55. A substantial fraction of 
well differentiated endometriod carcinomas (Type i) cases (31%:56; 85%:57 show nuclear 
β-catenin staining. Accordingly, loss- and gain-of-function mutations in members of 
the Wnt/β-catenin signaling pathway known to act as tumor suppressors (APC) and 
oncogenes (β-catenin) have also been identified. Mutation of β-catenin at its GSK-3β 
binding consensus site encoded by exon 3 and leading to its constitutive activation have 
been identified in 15-40 % of endometrial tumors58,59, whereas loss of heterozygosity 
(LOh) at the APC locus was observed in 24 % of the cases with nuclear β-catenin staining60. 
APC mutation analysis showed truncating mutations in 10% of all endometrial cancers61. 
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Moreover, the APC A1 promoter was found to be hypermethylated in 46.6% of 
endometrial cancers positive for nuclear β-catenin60, often in correlation with micro-
satellite instability62. Notably, these somatic mutations in members of the canonical 
Wnt pathway were preferentially found in Type i endometrial cancer, which accounts 
for about 85% of the total number of endometrial cancer cases. Enhanced estrogen 
signaling over a prolonged period of time is believed to be a causative factor for Type 
i endometrial cancer63. hence, although continuous estrogen induced Wnt/β-catenin 
signaling may represent an early step in endometrial tumorigenesis, tumor progression 
and malignant transformation seem to additionally require somatic mutations leading 
to the constitutive activation of the pathway.
Several genetically engineered mouse models have been employed to investigate 
the role of constitutive Wnt/β-catenin activation for endometrial malignancies. Tanwar 
et al. (2009)64 investigated the effects of conditional Wnt signaling activation in the 
uterus by Amhr2-Cre-driven oncogenic activation of β-catenin (Ctnnb1tm1Mmt/+).  The 
Amhr2 gene is expressed as of mouse embryonic day 12.5 onwards in mesenchymal 
cells surrounding the Müllerian duct and in adult mice in the myometrium. The 
corresponding Amhr2Cre/+;Ctnnb1tm1Mmt/+ mice develop myometrial hyperplasia and 
mesenchymal tumors (similar to leiomyomas) and endometrial sarcomas. furthermore, 
hyperplasia of endometrial glands was occasionally observed in the uterus, suggesting 
that mesenchymal activation of Wnt/β-catenin signaling plays a role in the early events 
of epithelial tumorigenesis in the endometrium. Jeong et al. (2009)65 employed Pgr-Cre 
to drive oncogenic activation of β-catenin (PgrCre/+;Ctnnb1f(Ex3)/+) and of canonical Wnt 
signaling in a broad spectrum of uterine cells (endometrium and myometrium). These 
authors could show that activation of Wnt/β-catenin signaling in the uterus resulted 
in enhanced proliferation of glandular epithelial cells, endometrial hyperplasia at 6 
weeks of age, and in defective estrogen signaling, though not in endometrial cancer. 
These results suggest that constitutive activation of Wnt/β-catenin signaling on its 
own is insufficient for endometrial cancer onset and may possibly also indicate that 
the synergistic action of additional downstream effectors of estrogen signaling are 
necessary for full-blown malignant transformation. however, as predicted by the just-
right signaling model66-67, different levels of pathway activation may differently trigger 
tumorigenesis in distinct tissues. Therefore, it would be of interest to investigate the 
consequences of hypomorphic mutations in members of the Wnt pathway other than 
β-catenin whose oncogenic activation invariably leads to extremely high Wnt signaling 
levels.
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1.6 ThE RELATiONShiP BETWEEN SEx hORMONE ACTiON 
AND WNT/β-CATENiN SiGNALiNG iN ThE ENDOMETRiUM
Signaling by both sex hormones and Wnt/β-catenin are actively involved in endometrial 
physiology and pathophysiology, and there are good indications that during the 
menstrual cycle, sex hormones can modulate Wnt/β-catenin signaling to maintain the 
balance between proliferation and differentiation (fig. 3). 
1.6.1 Estrogenic regulation of Wnt/β-catenin signaling. 
The putative mechanisms underlying estrogen-mediated Wnt/β-catenin activation 
in the uterus are at present poorly understood. A direct effect of ERα as an estrogen-
activated transcription factor modulating the expression of Wnt ligands, modulators 
and targets has been described by many authors: the ligands Wnt4, Wnt5A and Wnt7A 
have been shown to be induced by estradiol in the uterus33,68-71. in addition the Wnt 
inhibitor DKK1 was shown to be inhibited by estrogens in bone forming osteoblasts72 
and in the hippocampal CA1 region73 (DKK1 interacts with a co-receptor for canonical 
Wnt signaling, the low density lipoprotein receptor-related protein-6 (LRP6)74). 
furthermore, the Wnt-target gene WISP2 (Wnt1-induced signaling pathway protein 2) 
was shown to be up-regulated through direct interaction of activated ERα with its 
promoter region in human breast cancer cells75. 
The estrogen-activated ERα, however, can also function as a modulator of 
transcription, without directly binding to DNA sequences in the promoter region of the 
affected genes. for example, Shi et al. (2007)77 could show that EZh2 (the polycomb 
group protein enhancer of zeste homolog 2) physically interacts with ERα and 
β-catenin. hence, estradiol can affect the transcription of Wnt/β-catenin target genes 
without directly interacting with estrogen response elements at the DNA level. 
furthermore, ERα has also been observed to associate with important growth 
factor pathways such as the Pi3K pathway thus indirectly cross-talking with canonical 
Wnt signaling78,79. Binding of estrogen-activated ERα to p85 (PiK3R2), the regulatory 
subunit of Pi3K, activates AKT which results in inhibition of GSK-3β. This, in turn, 
prevents N-terminal Ser/Thr phosphorylation of β-catenin, enhances its intracellular 
stabilization and eventual allows for translocation to the nucleus, where it complexes 
with members of the TCf/LEf transcription factor family and leads to the activation of 
Wnt target genes80,81 (fig. 4A and fig. 3). 
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Figure 4. Mechanisms of estrogenic (A) and progestagenic (B) regulation of Wnt/β-catenin signaling in the 
human or mouse endometrium.  Adapted from 76. Akt, protein kinase B; E2, estradiol; EZh2, enhancer of 
zeste homolog 2; fZD, frizzled receptors; iRS-1, insulin receptor substrate 1; LRP, low-density lipoprotein 
receptor related protein; Prg, progesterone; TCf, T-cell factor.
1.6.2 Progestagenic regulation of Wnt/β-catenin signaling
A role for progesterone in regulating Wnt/β-catenin signaling was suggested by Kao 
and Elinson (1998)82 and Tulac et al. (2006)83 who observed a profound progesterone 
specific increase in expression of the Wnt/β-catenin signaling inhibitor DKK1 in 
endometrial stroma cells during the secretory phase of the menstrual cycle. Using the 
antiprogestagen mifepristone (RU486), Catalano et al. (2007)84 could indeed confirm 
progestagen regulation of many Wnt/β-catenin pathway components. furthermore, 
Kane at al. (2008)85 subsequently showed that TGfβ1 attenuates both the expression 
of PR and DKK1 in differentiated endometrial stromal cells corroborating a close link 
between progesterone and Wnt/β-catenin signaling. fOxO1 is also an interesting 
molecule, as it has been shown to physically interact with the progesterone receptor 
to coordinate cell cycle regulation and differentiation of human endometrial stromal 
cells86. furthermore, fOxO1 is also able to interact with β-catenin87-88, thus being able 
to directly inhibit Wnt/β-catenin signaling89.  
Another pathway likely to play a role in regulating the interplay between 
progesterone and Wnt/β-catenin signaling is the hedgehog signaling pathway. 
Combined endometrial microarray data from different stages of the menstrual cycle17 
and from E2 only or E2+MPA treated patients51 indicated profound sex hormone 
regulation of hedgehog signaling. Mammals have three different hedgehogs, Sonic 
(Shh), indian (ihh), and Desert (Dhh). The ihh, the common hedgehog receptor 
patched (PTCh), and the target gene GLI1 encoding the transcription factor GLi1 
that is implicated in the hedgehog signaling pathway, are all up-regulated upon 
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estrogen signaling and down-regulated by progesterone during the menstrual cycle. 
furthermore, it has been shown that when ihh expression is impaired, the downstream 
effects of progesterone are lost in the uterus90. As indicated, progesterone itself down-
regulates hedgehog signaling in the uterus and it has been shown that Wnt/β-catenin 
signaling may act downstream to ihh signaling91. 
Recently the link between hedgehog and Wnt/β-catenin signaling has also been 
confirmed for atypical endometrial hyperplasia and endometrial cancer, showing that 
in hyperplasia and in well differentiated endometrial cancers GLi1 overexpression 
correlated well with β-catenin nuclear immunoreactivity92. Because our own data 
on staining for the Wnt target gene CD44 indicated that progesterone can also act 
as a profound inhibitor of Wnt/β-catenin signaling in vivo in hyperplasia as well as in 
well differentiated endometrial cancer, a physiological and functional link between 
progesterone, hedgehog and Wnt/β-catenin signaling seems plausible. (fig. 4B and 
fig. 3)
1.7 STEM CELLS Of ThE ENDOMETRiUM
As briefly indicated above, the endometrium is a very dynamic tissue, which, in human, 
is partly replaced every 4 weeks, and in mice every 4 to 5 days. for other tissues with 
significant cellular turnover, such as the hematopoietic system, the epidermis and 
intestinal epithelium, somatic stem cells have been identified93-95. however, although 
the concept of stem or progenitor cells replenishing the endometrium was proposed 
three decades ago96, until now, direct evidence showing that the endometrium does 
have its own stem/progenitor cells is limited.
Chan et al. (2004) showed that, by plating out single human endometrial cells, 
0.08% of endometrial epithelial cells and 0.02% of stromal cells formed large colonies 
which could be replated several times97. Epithelial markers, such as BerEP4, CD49f and 
cytokeratin, and stromal markers such as 5B5, αSMA and CD90 could be identified in 
epithelial and stromal colonies, respectively. further, Gargett et al. (2009) showed that 
epithelial colonies in matrigel could form cytokeratin expressing glandular structures. in 
addition depending on the differentiation-induction medium, stromal colonies showed 
differentiation into the myogenic lineage (αSMA and caldesmon staining), osteogenic 
lineage (alkaline phosphatase reactivity and expression of PThR1), adipogenic lineage 
(Oil Red O and lipoprotein lipase (LPL) staining) and chondrogenic lineage (alcian blue 
and collagen type ii staining)98. Other research on the identification of endometrial 
stem cells involved an interesting finding that in bone-marrow transplanted patients, 
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donor-derived bone marrow cells could be found in the endometrial epithelium and 
stroma99.  This experiment was confirmed in lethally irradiated female mice that were 
transplanted with bone marrow derived from constitutively LacZ expressing male mice, 
showing > 0.5% of epithelial endometrial cells originating from the male donor100, 101.
The above-mentioned studies, aimed at the identification of stem/progenitor 
cells, all suffer from a major drawback that although stem/progenitor cells seem to be 
present in the endometrium, these cells cannot be recognized as such in their original 
niche, neither can they be specifically isolated for further research. 
One approach to identify and isolate stem-like cells is by sorting by fACS a population 
of cells on the basis of low staining by the fluorescent vital DNA binding dye, hoechst 
33342102. These cells are called side population cells (SP cells), and due to high expression 
of ABCG2/Bcrp1 transporter proteins, stem-like cells actively remove hoechst 33342 
from their cytoplasm103. This characteristic was used to isolate cancer stem cells in 
several malignancies including acute myelogenous leukemia, neuroblastoma, glioma 
and lung cancer104-108. for the human endometrium Tsuji et al. (2008) isolated SP cells 
that were initially in the G0 phase of the cell cycle and which showed greater colony 
forming efficiency than non-SP cells109. The fact that isolated SP cells were in G0 is 
reminiscent of the common suggestion that stem cells are a relatively quiescent cell 
population. furthermore, under decidualizing conditions colony forming endometrial 
SP cells started to secrete prolactin which is in agreement with the receptive nature 
of the endometrium towards an implanting embryo. Cervello et al. (2010) went a step 
further and showed in vitro differentiation of SP cells into adipogenic and osteogenic 
lineages. Moreover, after subcutaneous injection of SP cells in NOD-SCiD mice, these 
authors observed the development of human endometrium-like structures110.
Another approach to find stem cells in the endometrium is by staining the tissue 
for known stem cell markers. for example, recently a population of single cells and cell 
groups in the stroma adjacent to the myometrium was identified that expressed the 
putative stem cell marker Musashi-1111. interestingly this marker was also found to be 
expressed at increased levels in endometriosis and endometrial carcinoma112. 
Taking advantage of the finding that stem cells may be infrequently dividing 113, two 
methods have been developed to identify these cells on the basis of label retention 
(label retaining cells; LRCs). Mice are labeled using a traceable exogenous DNA marker 
such as bromodeoxyuridine (BrdU)114,115 or using an inducible hybrid DNA binding 
transgene such as histone-2B GfP (h2B-GfP). Subsequently, in each cell division the 
label is washed-out except for in non- or infrequently-dividing stem-like cells. Using 
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BrdU labeling Gargett116 identified slowly dividing cells in the endometrium. They 
observed that after 12 weeks of chase, no LRCs were present in the luminal and glandular 
epithelium, and stromal LRCs were observed at the endometrial-myometrial junction 
in close proximity to the blood vessels. At 8 weeks of chase, however, approximately 3% 
of endometrial epithelial cells still retained their label. These ER-negative LRCs were, in 
contrast to the authors expectations, present in the luminal epithelium.
The inducible h2B-GfP system to label DNA has been used with great success to 
identify stem cells in the hematopoietic system117-119, hair follicles120, and rectum121 , 
but has not been used before, to study the mouse endometrium. 
 
1.8 OUTLiNE Of ThiS ThESiS 
Cyclic renewal and functional differentiation of the inner layer of the uterus depends 
on hormonal regulation of a group of cells which is able to rapidly repopulate 
the functionalis layer of the endometrium. The cells which are at the origin of the 
repopulation, endometrial progenitor cells, are induced to proliferate by estradiol and 
induced to differentiate by progesterone. 
in Chapter 1 the importance of sex hormonal and Wnt signaling in endometrial 
homeostasis and tumorigenesis is addressed. To further the role of Wnt/βcatenin 
signaling in more detail, and in particular to study what is the effect of loss of APC 
expression in the uterus, we conditionally inactivate the endogenous Apc gene from 
early embryonic life onwards in mesenchymal cells surrounding the Müllerian duct. 
The results are presented in Chapter 2.
As described in Chapter 3, we investigated how progesterone counteracts the 
proliferative effects of E2 during the normal menstrual cycle, during hyperplasia, 
and during early endometrial carcinogenesis. The molecular mechanistic evidence is 
provided.
The research described in Chapter 4 focused on the question whether we could 
identify stem cells in the female urogenital tract. To answer this question, we have 
employed a non-mutagenic and cell cycle independent approach, namely in vivo 
pulse-chase with the histone 2B - green fluorescent protein (h2B-GfP) towards the 
identification and prospective isolation of long-term LRCs (LT-LRCs) in the mouse 
female reproductive tract. The characteristics of the LT-LRCs were described. 
Chapter 5 and 6 provides a summary of the main findings of the present research. 
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ABSTRACT
The Wnt signal transduction pathway plays a rate limiting role in early development of 
many different organs. To study the functional consequences of constitutive activation 
of the canonical Wnt pathway in the developing uterus, we generated a novel mouse 
model where loss of the tumor suppressor gene Apc was induced. A mouse model was 
generated and evaluated where Amhr2Cre/+ driven loss of Apc exon 15 was induced. 
The Apc recombination was detected mainly in the myometrial layer of the adult 
uterus. A significant loss of muscle fibers in myometrium was apparent, though with 
very few muscle cells earmarked by nuclear β-catenin. The finding was confirmed 
in the PgrCre/+;Apc15lox/15lox mouse model. Loss of APC function in mesenchymal cells 
surrounding the fetal Müllerian ducts results in severe defects in the myometrial layers 
of the uterus in adult mice, suggesting that the WNT signaling pathway plays important 
roles in maintaining myometrial integrity.
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iNTRODUCTiON
Shortly after the onset of testis differentiation during mammalian embryonic life, the 
first testicular hormone to be produced is anti-Müllerian hormone (AMh), secreted 
by the Sertoli cells, soon followed by production of testosterone by the Leydig cells. 
fetal testosterone production stabilizes the Wolffian ducts, which give rise to the 
epididymides and vasa deferens. AMh binds to its receptors on the mesenchymal cells 
surrounding the Müllerian ducts, which induces apoptosis and results in Müllerian 
duct regression. Because embryonic female gonads do not produce any testosterone 
or AMh, Wolffian ducts will regress and Müllerian ducts are stabilized to form the upper 
part of the vagina, the uterus and the oviducts1. for the current investigations, we 
developed and analysed a novel mouse model to study the role of canonical Wnt/β-
catenin signalling in embryonic development and homeostasis of the uterus.
in canonical Wnt/β-catenin signalling, a central role is played by the “destruction 
complex” consisting of three scaffolding proteins, namely AxiN1, AxiN2, and APC 
(adenomatous polyposis coli), two kinases, glycogen synthase kinase-3β (GSK3β) 
and casein-kinase 1α (CK1α), and β-catenin (CTNNB1). in the absence of extracellular 
Wnt ligands, formation of the destruction complex marks β-catenin by Ser-Thr 
phosphorylation, thus promoting its proteolytic degradation through ubiquitination. in 
the presence of Wnt signals however, formation of the destruction complex is inhibited 
and β-catenin is able to accumulate in the cytoplasm and eventually translocate to 
the nucleus where, in association with members of the TCf/LEf family of transcription 
factors, it activates transcription of a broad spectrum of downstream target genes (http://
www.stanford.edu/~rnusse/pathways/targets.html). Defects in several members of 
the Wnt signalling cascade, i.e. loss of function mutations at the APC gene, result in 
the accumulation of intracellular and nuclear β-catenin, thus leading to constitutive 
deregulation of target genes2-6. During the early phases of development of the female 
reproductive tract, Wnt ligands such as Wnt4, Wnt5a and Wnt7a play an important role7-9. 
Wnt4 knock-out female mice develop normal Wolffian ducts but lack Müllerian ducts9. 
Wnt5a knock-out female mice are characterized by defects in the posterior outgrowth 
of the developing Müllerian ducts and in forming endometrial glands7. Loss of Wnt7a 
expression on its turn, leads to incomplete demarcation between the vagina and the 
uterus and between the uterus and the oviduct. furthermore, Wnt7a knock-out female 
mice do not form uterine glands and show myometrial aberrations8. 
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More recently, two models have been developed to evaluate the consequences of 
conditional Wnt/β-catenin activation in the uterus10-11. Jeong et al. (2009) investigated 
the effects of conditional activation of Wnt signaling in the uterus by PgrCre driven 
activation of β-catenin expression (PgrCre/+;Ctnnb1f(Ex3)/+) and showed profound 
endometrial hyperplasia, which did not further progress to endometrial cancer 10. 
Tanwar et al. (2009) employed the Amhr2 (Amh type 2 receptor) promoter to drive 
Cre expression (Amhr2Cre/+) and activate β-catenin expression in mesenchymal cells 
surrounding the developing Müllerian ducts. This approach resulted in myometrial 
hyperplasia, adenomyosis, and mesenchymal tumors similar to leiomyomas and 
endometrial stromal sarcomas11.  furthermore, hyperplasia of endometrial glands 
was occasionally observed suggesting that mesenchymal activation of Wnt/β-catenin 
signalling plays a role in the early events which may lead to endometrial carcinogenesis. 
in approximately 40% of human endometrial cancers, nuclear β-catenin staining is 
observed12-13, and in over 50% of these cases loss of APC expression is involved (either 
LOh or promoter methylation14). in order to further clarify the role of Wnt/β-catenin 
signalling, and in particular loss of Apc expression in the uterus, we bred Amhr2Cre/+mice15 
with Apc15lox/15lox mice16 to conditionally inactivate the endogenous Apc gene from early 
embryonal life onwards in mesenchymal cells surrounding the Müllerian duct. 
MATERiALS AND METhODS
Animals and genotyping
All experiments conducted with mice were approved by our local animal ethics 
committee (DEC permit number EUR 1076) and were in accordance to international 
guidelines and regulations. Amhr2-LacZ animals17-18 and Amhr2Cre animals15 were 
obtained from Dr RR Behringer. Amhr2Cre mice were bred with Rosa26 reporter mice 19 
to review Cre expression, and were bred with Apc15lox mice16,20  to obtain Apc15flox/15flox 
mice (“flox” means that the sequence between two loxP sites has been deleted by Cre). 
PgrCre animals21 were also bred with Apc15lox mice to obtain Apc15flox/15flox mice. All animals 
were maintained in a C57Bl/6J background. Genotyping was performed by routine PCR, 
on tail and uterus DNA, using the following primers: detection of the 380 bp Apc15lox 
allele: TAGGCACTGGACATAAGGGC and GTAACTGTCAAGAATCAATGG; detection of the 
450 bp Apc15flox allele: AACTTCTGAGTATGATGGAGG and GTAACTGTCAAGAATCAATGG; 
detection of the 219 bp Cre allele: GGACATGTTCAGGGATCGCCAGGC and 
CGACGATGAAGCATGTTTAGCTG; detection of the 500 bp Rosa26-LacZlox and 250 bp 
Rosa26-LacZflox allele: AAAGTCGCTCTGAGTTGTTAT, GCGAAGAGTTTGTCCTCAACC 
and GGAGCGGGAGAAATGGATATG. for all animals, the stage of the estrous cycle was 
determined by a vaginal smear just before sacrifice. 
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β-Galactosidase staining
The β-galactosidase staining was performed as described before22 with the adaptation 
that here Bluo-Gal (invitrogen, Breda, The Netherlands) was used instead of x-gal. fixed 
uteri were stained with Bluo-Gal overnight, embedded in paraffin, sectioned (5 µm) 
and counter-stained with eosin.
Laser microdissection 
Paraffin-embedded tissues were sectioned (10 µm), adhered to uncoated microscope 
slides and stained with haematoxylin and eosin. Laser microdissection was performed 
by PALM laser microdissection (Carl Zeiss Microimaging Gmbh, Standort Göttingen, 
Germany). Approximately 1 mm2 of myometrium, luminal epithelium and stromal 
tissue combined with glandular epithelium were collected, respectively. DNA was 
extracted from these tissues compartments, using a phenol-chloroform method. The 
genotypes of different uterine layers were assessed by PCR as described above.
immunohistochemistry 
immunohistochemistry was performed essentially as described before23. The antibodies 
employed are: mouse monoclonal anti-SMA (DAKO, heverlee, Belgium) (1:150), rat 
monoclonal anti-cytokeratine 8 (CK8, 1:5000) (DShB, iowa, USA), rabbit polyclonal anti-
ERα (Millipore, Billerica, USA) (1:2000) and rabbit monoclonal anti-β-catenin (Epitomics, 
Burlingame, USA) (1:800).
histological view and measurement 
immunohistochemical staining for smooth muscle actin (SMA), which stains 
myometrium, was applied to distinguish between myometrium and endometrium. 
CK8 was used to specifically stain epithelial cells. Nanozoomer Digital Pathology (NDP) 
(hamamatsu Photonics Deutschland Gmbh, herrsching am Ammersee, Germany) was 
used to scan the slides and this program also allowed for uterine area measurements. 
The number of glands was measured per square millimeter of endometrium. Of each 
evaluated uterus, every 2mm one section was measured (7 sections per uterus), and in 
total thirteen control and ten experimental animals were assessed. 
Statistical methods 
Analyses were performed using Graphpad Prism 5 (GraphPad Software, inc., San Diego, 
CA). Unpaired, two-tailed t-test was used to analyze the differences between groups. 
P values lower than 0.05 were considered statistically significant. 
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RESULTS 
The Amhr2 promoter is mainly active in the myometrium
first we established the pattern of expression driven by the promoter of Amhr2 in the 
uterus by employing previously developed Amhr2-LacZ reporter mice17. As shown in 
figure 1A, LacZ expression was limited to the myometrial layer of the uterus. This result 
was confirmed by breeding Amhr2Cre/+ transgenic animals with the Rosa26 reporter mice 
(R26R) carrying a loxP-STOP-loxP-lacZ reporter19. in the presence of active Cre, somatic 
deletion of the STOP cassette is achieved, thus leading to β-galatosidase expression 
from the LacZ gene. figure 1B shows β-galatosidase staining of both myometrial 
layers (inner circular and outer longitudinal muscles) in compound Amhr2Cre/+;R26R 
animals. Notably, staining was not continuous throughout the myometrium as 
exemplified by patchy β-galactosidase expression within the outer myometrial layer, 
which is in accordance with a previous publication by Deutscher and Yao24. Staining 
for β-galactosidase also indicated that the Amhr2 promoter is not active in stromal and 
epithelial cells of the endometriumNext, Amhr2Cre animals were bred with Apc15lox/15lox 
animals, a model developed by our laboratory16 to conditionally inactivate Apc function 
by removing exon 15 of the endogenous gene. Deletion of both Apc alleles results in the 
constitutive activation of Wnt/β-catenin signaling. To substantiate that Cre expression 
in the compound Amhr2Cre/+;Apc15lox/15lox animals was limited to the myometrial layer, 
and to verify that recombination of the Apc gene was indeed taking effect, laser capture 
microdissection (LCM) of different layers of the uterus was performed. As illustrated in 
figure 1C and 1D, only a small percentage of cells from the stromal/glandular region 
showed Apc exon 15 deletion, whereas no somatic recombination was detected in 
the luminal epithelial region. in contrast, Apc deletion was evident in cells from in the 
myometrium. 
Next, Amhr2Cre animals were bred with Apc15lox/15lox animals, a model developed by 
our laboratory 16 to conditionally inactivate Apc function by removing exon 15 of the 
endogenous gene. Deletion of both Apc alleles results in the constitutive activation 
of Wnt/β-catenin signaling. To substantiate that Cre expression in the compound 
Amhr2Cre/+;Apc15lox/15lox animals was limited to the myometrial layer, and to verify that 
recombination of the Apc gene was indeed taking effect, laser capture microdissection 
(LCM) of different layers of the uterus was performed. As illustrated in figure 1C and 1D, 
only a small percentage of cells from the stromal/glandular region showed Apc exon 
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15 deletion, whereas no somatic recombination was detected in the luminal epithelial 
region. in contrast, Apc deletion was evident in cells from in the myometrium. 
Somatic Apc deletion is predicted to result in the constitutive activation of the 
canonical Wnt pathway and, possibly, in the nuclear accumulation of β-catenin16,25. 
however, ihC analysis of β-catenin expression in the uterus of Amhr2Cre/+;Apc15lox/15lox 
animals revealed that the majority of myometrial cells are marked by cytoplasmatic 
β-catenin staining with only few cells showing nuclear staining (fig. 1E). This result is in 
agreement with previous studies from our and other laboratories showing that loss of 
Apc function is necessary but often insufficient for nuclear β-catenin accumulation26,27.
Figure 1. Amhr2 promoter activity and Apc recombination in different regions of the uterus. A: Amhr2-
LacZ mice were stained for β-galactosidase activity with Bluo-Gal. B: Amhr2Cre/+;R26R  animals were stained 
for β-galactosidase activity. C: indicated different layers of the uterus that were isolated by microdissection 
for DNA isolation. (0), before dissection; (1), glands and stroma; (2), luminal epithelium; (3), myometrium. 
D: Representative gel-image from a PCR reaction to determine recombination of Apc using DNA isolated 
from an Amhr2Cre/+;Apc15lox/15lox mouse: (1), stroma and glands; (2) luminal epithelium; (3) myometrium. Apc15lox 
represents the non-recombined lox allele; Apcflox indicates recombination of Apc; Actin was used as a control 
for PCR. L/L represents DNA displaying both non-recombined Apc15Lox alleles; f/L represents DNA displaying 
one non-recombined and one-recombined Apc allele. Primers used for the PCR are described in Materials 
and Methods. E: β-catenin staining of a representative Amhr2Cre/+;Apc15lox/15lox mouse. The arrows indicate 
myometrial cells which show nuclear β-catenin staining. Luminal and glandular epithelial cells only show 
cytoplasmic and membrane β-catenin staining. Control animals never showed nuclear β-catenin staining. 
236
Loss of APC function results in myometrial defects
histological assessment of uteri from adult compound Amhr2Cre/+;Apc15lox/15lox mice 
revealed severe defects in the myometrium (an overview of the analyzed mice is 
presented in Table 1). To investigate the nature of these defects in more detail, smooth 
muscle actin (SMA) ihC staining was employed to specifically mark the myometrium. 
As shown in figure 2, in contrast to control animals (fig. 2A), all Amhr2Cre/+;Apc15lox/15lox 
animals showed regions within the myometrium where the muscle layer appeared 
disorganized or even discontinuous (fig. 2B). Out of the 19 Amhr2cre/+;Apc15lox/15lox mice 
here examined, 16 showed tissue architectural changes of the myometrium without 
interruption of the myometrium layer, as exemplified in figure 2B (top panel). in the 
other 3 of 19 animals the same architectural changes in the myometrium appeared 
in association with a discontinuous myometrium layer, as exemplified in panels 2 and 
3 of figure 2B. Pregnancies in Amhr2Cre/+;Apc15lox/15lox animals only resulted in life born 
puppies in 2/4 cases. On the other 2/4 cases the mother died during delivery. in order 
to investigate these delivery problems futher, we tried to obtain permission with our 
local animal ethics committee, but it was not allowed.  
To obtain additional evidence that loss of Apc function in myometrial cells of the 
uterus indeed results in muscular defects in the adult uterus, Apc15lox/15lox animals were 
bred with PgrCre animals. in these animals nuclear β–catenin staining was readily 
detected in the myometrium and in epithelial cells of the endometrium (fig. 3A). 
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Figure 2. Amhr2Cre/+;Apc15lox/15lox mice show myometrial defects. The uterine muscle was stained with an 
antibody against Smooth Muscle Actin (SMA) A: three control animals at different stages of the estrous cycle: 
from top to bottom: proestrus, estrus and diestrus. The staining shows a cellular myometrium with closely-
packed muscle fibers. B: Three Amhr2Cre/+;Apc15lox/15lox mice, matched for age and stage of the cycle to the 
controls. The top figure shows an affected uterus where the outer part of the myometrium contains tightly 
packed fibers, but the inner part shows more dispersed and thinner fibers. The middle and bottom figures 
show a complete trans-section of the uterus where the muscle wall is focally incomplete.
Figure 3. PgrCre/+;Apc15lox/15lox mice also display myometrial defects. β-catenin (A) and SMA (B) staining of a 
representative PgrCre/+;Apc15lox/15lox mouse. Details on the right indicate presence of glandular and stromal cells 
in the muscle layer. Gland (red arrow), stroma (black arrow) and myometrium (green arrow). 
furthermore, marked myometrial defects were detected in the majority of investigated 
animals (7/10) (fig. 3B). interestingly, omissions in the myometrial layer were invaded 
by stromal and glandular cells from the endometrium reminiscent for a human disorder 
described as endometriosis interna or adenomyosis28.
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in order to assess the underlying basis for the effects of the induced Apc mutation, 
embryonal mice were sacrified and the Müllerian ducts were stained for apoptosis 
(caspase-3). Time of sacrifice (E12) was chosen based on our own data in Amhr2Cre/+; 
R26R-LacZ animals showing clear Cre activity around that day. No differences, however, 
were detected between controls and Amhr2Cre/+;Apc15lox/15lox littermates (data not shown). 
Endometrial defects in Amhr2cre/+;Apc15lox/15lox mice
Although recombination of Apc15lox alleles in the endometrium could hardly be 
detected in the Amhr2Cre/+;Apc15lox/15lox animals, phenotypic expression of gene deletion 
was apparent from observed differences between targeted and control animals, 
such as a smaller endometrial area and less endometrial glands. To quantify these 
differences, anti-SMA was used to stain myometrium, and anti-CK8 was used to stain 
endometrial glands (fig. 4A and 4B). As indicated in Materials and Methods several 
areas were measured and gland numbers counted. Despite the myometrial defects 
described above, no significant differences could be detected in the myometrial area of 
Amhr2Cre/+;Apc15lox/15lox animals when compared with control animals (fig. 4C). however, 
significant differences were observed for the number of glands per mm2 (fig. 4D, p = 
0.0001) and the area of the endometrium (fig. 4E, p = 0.0002): Amhr2Cre/+;Apc15lox/15lox 
mice show fewer glands and a reduction of the endometrial area. 
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Figure 4. Quantification of endometrial and myometrial defects in Amhr2Cre/+;Apc15lox/15lox mice. A: a cross 
section from a control uterus stained for smooth muscle actin and counterstained with hematoxylin. 
indicated regions provide information on the area of the myometrium and endometrium. B: consecutive 
section was stained for cytokeratine 8 in order to measure the number of endometrial glands. C: calculation 
of the myometrial area in control and affected animals D: measurement of the number of glands per area of 
stroma in control and affected animals. E: calculation of the endometrial area in control and affected animals. 
The panels C-E were derived from 13 controls and 10 Amhr2Cre/+;Apc15lox/15lox mice (7 sections per animal). Con 
= control animals; Cre-lox = Amhr2Cre/+;Apc15lox/15lox animals. Data are presented as: Mean (line), 25th and 75th 
percentiles (box), and 5th and 95th percentiles (whiskers).
Supplementary Figure 1.   Endometrial stromal sarcoma-like lesion observed in one Amhr2Cre/+;Apc15lox/15lox 
mouse. A and B: hematoxylin/eosine staining of the affected uterus showing the lesion (red circle indicates 
the aberrant region); the square indicates the magnified region depicted in figure b B. Consecutive sections 
were stained for SMA (C), Estrogen Receptor alpha (D) and β-catenin (E).  
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DiSCUSSiON
The functional role of canonical Wnt/β-catenin signalling in uterine development 
and homeostasis is to date largely unclear. Recently, Jeong et al. (2009) investigated 
the effects of conditional activation of Wnt signaling in the uterus by PgrCre driven 
expression of oncogenic β-catenin (PgrCre/+;Ctnnb1f(Ex3)/+)10. The progesterone receptor, 
however, is widely expressed throughout the uterus from week two after birth onwards, 
and accordingly a broad spectrum of defects was observed: the PGRCre/+;Ctnnb1f(Ex3)/+ 
animals showed reduced offspring numbers  resulting from a diminished decidual 
reaction, decreased uterine weight, increased ERα expression in the endometrium, 
enlarged endometrial glands, endometrial hyperplasia, and increased endometrial 
proliferation. 
in the present study the aim was to investigate the consequences of Wnt/β-catenin 
activation by Apc deletion in embryonal life for specific adult uterine tissues. in 
particular, the Amhr2 promoter was employed to drive Cre expression to induce loss of 
Apc function (Amhr2Cre/+;Apc15lox/15lox) in the myometrium but not in the endometrium. 
The main difference between the current approach and studies by others on the role 
of Wnt/β-catenin signaling in the uterus10-11,24,29 is that here conditional knock-down of 
Apc is used (others use conditional inactivation or activation of β-catenin). The role of 
APC of course is different from the role of β-catenin: APC is involved in cell adhesion, 
migration, apoptosis and chromosomal segregation30. This is true, however, the main 
tumor-suppressing function of APC instigates from its role in the Wnt/β-catenin 
signalling pathway.
Previous studies with the Amhr2-LacZ reporter mouse model showed that this 
promoter is active for a brief period from embryonic day 12.5 to 15.5 in mesenchymal cells 
surrounding the Müllerian ducts15,17,31. Notably, in a related reporter model, Amhr2Cre-
driven recombination of a Rosa26 reporter (R26R) resulted in β-galactosidase staining 
of myometrial cells but not in endometrial stromal cells17,24. This observation was 
confirmed in the current study also by assessing somatic recombination of the Apc15lox 
allele in laser-capture microdissected areas of the uterus of Amhr2Cre/+;Apc15lox/15lox mice 
(fig. 1). 
A more detailed approach to the determination of Cre-mediate recombination 
efficiency is represented by β-catenin immunohistochemical staining. Nuclear β-catenin 
accumulation is often regarded as a hallmark of Wnt/β-catenin signalling activation as 
the result of loss of Apc function. however, β-catenin ihC analysis of the myometrium 
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of Amhr2Cre/+;Apc15lox/15lox animals revealed a majority of cells with cytoplasmatic staining 
and only very few, sporadic cells with clear-cut nuclear staining. This is consistent with the 
observed patchy β-galactosidase staining (fig. 1B). furthermore, Miclea et al. (2009) and 
Robanus-Maandag et al. (2010) showed increased intracellular β-catenin staining upon 
somatic Apc deletion with only a minority of cells featuring nuclear accumulation16,20. 
interestingly these authors did show a clear phenotype resulting from the intestinal 
Cre-mediated deletion of Apc: tumors in the large intestine16. Accordingly, other reports 
have shown that loss of APC function is necessary but not always sufficient for nuclear 
β-catenin accumulation 26-27. in contrast to this, PgrCre/+;Apc15lox/15lox animals did show 
nuclear β-catenin staining indicating that recombination of Apc can indeed result in 
nuclear β-catenin staining. There is however a considerable difference between the 
two models: Amhr2Cre is activated only from embryonal day 12.5 to 15.5 while PgrCre 
becomes active and stays active from approximately postnatal day 10 onwards. it is 
possible that the majority of mesenchymal cells surrounding the embryonal Müllerian 
duct (where loss of Apc function is established) selectively undergo apoptosis, while 
more mature myometrial cells in which Apc is knocked down, do not. in fact apoptosis 
as a result of activation of Wnt/β-catenin signalling has previously been shown for 
Nih-3T3 fibroblasts32. The latter would also be in agreement with the observed loss of 
myometrial muscle tissue in some of the animals upon Apc somatic deletion, described 
herein (fig. 2 and 3). Reviewing Müllerian duct sections from embryonal day 14 
Amhr2Cre/+;Apc15lox/15lox animals, however, failed to show increased apoptosis as measured 
by caspase 3 staining (data not shown). Evaluation of the uterus of PgrCre/+;Apc15lox/15lox 
animals indicated that it can not be excluded that loss of myometrial muscle fibers 
develops gradually over a prolonged period of time, or alternatively from pubertal life 
onwards.
The most prevalent phenotype observed among Amhr2Cre/+;Apc15lox/15lox mice is 
undoubtedly represented by the loss and disorganisation of myometrial muscle fibres 
resulting in a defective myometrium. Myometrial defects were also observed by others 
by employing comparable models to either induce or inhibit Wnt/β-catenin signalling 
in utero. Arango et al. (2005) used the Amhr2Cre model to induce β-catenin depletion 
and observed profound myometrial defects29. in that study, β-catenin depletion in 
mesenchymal cells surrounding the Müllerian ducts resulted in the appearance of 
adipocytes replacing myometrial cells. Miller and Sassoon (1997) found that in Wnt7a 
defective animals, among many other disorders, the myometrial layer became largely 
disorganized8. Tanwar et al. (2009) used a model which mimics more closely our approach 
in that Amhr2Cre was employed to express an oncogenic variant of β-catenin thus 
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inducing constitutive Wnt activation in the uterus11. however, in that study the affected 
animals developed muscular hyperplasia already at 6 weeks of age, which is substantially 
different from the current findings in Amhr2Cre/+;Apc15lox/15lox mice. Tanwar et al. (2009) 
also observed mesenchymal tumors with characteristics of human leiomyomas and 
endometrial stromal sarcomas11. To investigate whether similar neoplastic lesion could 
be observed in the Amhr2Cre/+;Apc15lox/15lox mice, we carefully reviewed all our mice but 
did not observe any leiomyomas. however, we did observe, in a single mouse, a region 
reminiscent of an endometrial stromal sarcoma-like lesion (Supplementary fig. 1). 
This region was subsequently stained for SMA, ERα and β-catenin. it was observed 
that ERα and β-catenin expression were both enhanced in this region, which was in 
agreement with the observations done by Tanwar et al.11.
Recently, we have extended our analysis on the consequences of loss of Apc 
function in the uterus by employing PgrCre mice (fig. 3). Myometrial breakdown in 
PgrCre/+;Apc15lox/15lox animals was to some extent comparable to myometrial defects 
in Amhr2Cre/+;Apc15lox/15lox animals. however, PgrCre/+;Apc15lox/15lox animals were also 
characterized by areas in the myometrium nearing some similarity to human 
adenomyosis, a condition characterized by the presence of endometrial tissue 
within the myometrium. Accordingly, Tanwar et al. (2009) occasionally also observed 
glands and stroma in the muscle of Amhr2Cre/+;Ctnnb1f(Ex3)/+ animals11. Because in the 
Amhr2Cre/+;Apc15lox/15lox model the integrity of the myometrium is mainly affected, this 
seems to indicate that the presence of endometrial tissue into the myometrial layer in 
the Wnt-activated mice may be the result of a passive process rather than signifying 
active invasion. Recent investigations by Mehasseb et al (2010) also indicate that 
invasion of stromal cells from adenomyosis is augmented by the presence of myocytes 
from affected uteri33.
in conclusion, we report that in vivo inactivation of the endogenous mouse Apc gene 
in mesenchymal cells surrounding the Müllerian ducts results in significant myometrial 
defects in adult mice. Overall, these results further consolidate the notion that Wnt/β-
catenin signalling is important for uterine development and homeostasis. 
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ABSTRACT
Wnt signaling regulates the fine balance between stemness and differentiation. here, the 
role of Wnt signaling to maintain the balance between estrogen-induced proliferation 
and progesterone-induced differentiation, during the menstrual cycle, but also during 
the induction of hyperplasia and carcinogenesis of the endometrium, was investigated. 
Endometrial gene expression profiles from E2 and E2+MPA treated postmenopausal 
patients were combined with profiles obtained during the menstrual cycle (PubMed; 
GEO DataSets). ishikawa cells were transfected with progesterone receptors and Wnt 
inhibitors DKK1 and fOxO1, measuring Wnt activation. Expression of DKK1 and fOxO1 
was inhibited by use of sequence specific short hairpins. furthermore, patient samples 
(hormone treated endometria, hyperplasia and endometrial cancer) were stained for 
Wnt activation using nuclear β-catenin and CD44. in vivo, targets and components of 
the Wnt signaling pathway (among them DKK1 and fOxO1) are regulated by E2 and 
progesterone. in Wnt-activated ishikawa cells progesterone inhibits Wnt signaling by 
induction of DKK1 and fOxO1. furthermore, using siRNA-mediated knockdown of both 
DKK1 and fOxO1, progesterone inhibition of Wnt signaling was partly circumvented. 
Subsequently, immunohistochemical analysis of the Wnt target gene CD44 showed 
that progesterone acted as an inhibitor of Wnt signaling in hyperplasia and in well 
differentiated endometrial cancer. Progesterone induction of DKK1 and fOxO1 results 
in inhibition of Wnt signaling in the human endometrium. This Wnt inhibitory effect 
of progesterone is likely to play a rate-limiting role in the maintenance of endometrial 
homeostasis and, upon its loss, in tumor onset and progression towards malignancy. 
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iNTRODUCTiON
The female sex hormones estradiol and progesterone play rate-limiting roles in the 
cyclical renewal of the inner layer of the uterus (endometrium). in the first half of the 
regular menstrual cycle, the proliferation phase, estradiol is required to expand the 
endometrial layer by inducing cell proliferation. in the second half of the menstrual 
cycle, the secretory phase, progesterone levels rise, which antagonizes estradiols’ 
proliferative activity by inducing differentiation of epithelial and stromal cells of the 
endometrium 1. This, inhibition of estradiol-induced proliferation by progesterone is 
crucial for the maintenance of homeostasis in the endometrium. 
increased estrogen signaling often underlies endometrial hyperplasia and is a 
well-established risk factor for endometrial cancer2. Because progesterone inhibits 
estrogen-induced endometrial proliferation, progesterone has been employed in its 
synthetic form, i.e. medroxyprogesterone acetate (MPA), in palliative treatment of 
advanced and recurrent endometrial cancer with modest though significant response-
rates (15-25%)3. Progesterone has also been employed as a primary treatment for 
endometrial carcinoma confined to the endometrial layer of the uterus, for example 
in pre-menopausal women determined to preserve fertility. Response-rates in these 
women can be up to 60%4-5, indicating that progesterone signaling in well differentiated 
endometrial cancer is a potent inhibitor of endometrial carcinogenesis.
Wnt/beta-catenin signaling has a central function in the maintenance and control 
of stem cell compartments where it regulates the fine balance between stemness 
(Wnt-On) and differentiation (Wnt-Off). This central role in homeostasis of adult stem 
cell niches is reflected by the frequent association of Wnt/beta-catenin signaling 
defects with different cancer types (e.g. breast, colon, stomach, liver, ovary, uterine, 
skin, etc). Central in canonical Wnt signaling is the so called “destruction complex”. This 
complex consists of the scaffold proteins APC (Adenomatosis Polyposis Coli), AxiN1 
or AxiN2 (conductin), β-catenin (CTNNB1), and the two kinases CK1 (casein kinase i) 
and GSK3β (Glycogen Synthase Kinase 3β). in the absence of Wnt ligands formation 
of the destruction complex induces phosphorylation of β-catenin which results in 
its degradation. Upon Wnt signaling, the destruction complex is not formed and 
consequent intracellular β-catenin accumulates and translocates to the nucleus. in 
the nucleus, β-catenin interacts with members of the TCf/LEf family of transcription 
factors, thus modulating the expression of a broad spectrum of Wnt downstream target 
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genes6. The latter include genes encoding for proteins with central roles in proliferation 
and survival, such as cyclin D1 (CCND1) and iGf1 (insuline-like growth factor 1), but 
also others relevant for migration and invasion (for example CD44). Constitutive 
activation of the Wnt pathway was first observed in familial Adenomatous Polyposis 
where individuals carrying a germline APC mutation developed intestinal polyps 
upon somatic inactivation of the wild type APC allele. Notably, in the vast majority of 
sporadic colorectal cancers Wnt signaling is constitutively activated as the result of 
somatic APC mutations. in the remaining cases, either oncogenic β-catenin mutations 
or alterations in genes encoding secreted proteins able to inhibit Wnt signaling such as 
DKK1 (dickkopf homolog 17) are found. 
in endometrial cancer, gene mutations leading to constitutive activation of 
canonical Wnt/β-catenin signaling are an early event8. Well differentiated endometrioid 
adenocarcinomas show nuclear β-catenin accumulation in at least 30% of the cases 
(31%9; 85%10). Accordingly, oncogenic β-catenin mutations have been identified in 15-
40% of endometrial carcinomas11-12 whereas loss of heterozygozity of APC was reported 
in 24% of cases with nuclear β-catenin staining13. in addition, the APC A1 promoter was 
found to be hypermethylated in 47% of endometrial cancers with nuclear β-catenin13 
often in correlation with micro-satellite instability14. APC mutation analysis revealed 
truncating mutations in 10% of all endometrial cancers15. 
in the endometrium, Wnt/β-catenin signaling is involved in a number of 
developmental processes. for example, it has been shown that Wnt4 is required for 
Müllerian duct initiation16, Wnt7A for subsequent differentiation17 and Wnt5A for 
posterior outgrowth of the female reproductive track 18. furthermore, Wnt/β-catenin 
signaling signaling has also been implicated in regulation of the normal menstrual 
cycle19-20. Nuclear β-catenin staining, for example, is observed during the proliferative 
phase of the menstrual cycle21. Likewise, Nei et al.21 showed the absence of nuclear 
β-catenin staining during the second half (differentiation phase) of the menstrual 
cycle. hence, inhibition of Wnt/β-catenin signaling may correlate with the inhibition of 
estradiol-induced proliferation. hou et al22 showed that estrogen-induced endometrial 
proliferation was effectively inhibited by the Wnt/β-catenin inhibitor SfRP2 and Jeong 
et al23 showed that correct β-catenin expression is vital for normal uterine function. 
As progesterone counteracts the proliferative effects of estradiol during the menstrual 
cycle, it may do so by inhibiting estradiol-induced Wnt/β-catenin signaling. 
Based on the above data, we postulate that progesterone counteracts the 
proliferative effects of estradiol during the normal menstrual cycle, during hyperplasia 
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and during early endometrial carcinogenesis by inhibiting Wnt/ β-catenin signaling. 
According to this hypothesis, sex hormones may modulate Wnt/β-catenin signaling in 
the normal and aberrant endometrium to maintain the balance between proliferation 
(Wnt-On) and differentiation (Wnt-Off). 
MATERiALS AND METhODS
Patients and patient samples
Postmenopausal hormone treated patients: A description of the inclusion and 
exclusion criteria, and the histological and molecular findings in the endometrium 
were documented earlier1,24. The study groups were: Control-group (8 subjects, no 
hormonal treatment)); Estradiol (E2) group (7 subjects, 2 mg of estradiol administered 
orally every day, starting 21 days prior to surgery); Estradiol + MedroxyProgesterone 
Acetate (E2+MPA) group (6 subjects, 2 mg estradiol + 5 mg MPA administered orally 
every day, starting 21 days prior to surgery). After treatment, endometrial tissue was 
dissected-out, RNA isolated and processed, and gene expression was measured using 
the Affymetrix U133plus2 GeneChips containing 54,614 probe sets, representing 
approximately 47.000 transcripts (Affymetrix, Santa Clara, CA, USA)
Premenopausal patients during different stages of the menstrual cycle: A 
description of the inclusion and exclusion criteria, and the histological and molecular 
findings in the endometrium were documented earlier25. The study groups were: PE, 
proliferative endometrium (4 subjects); ESE , early secretory endometrium (3 subjects); 
MSE, midsecretory endometrium (8 subjects); LSE, late secretory endometrium (6 
subjects). Endometrial tissue was dissected as described above, and isolated RNA was 
used on the same microarrays as described above (Affymetrix U133plus2 GeneChip). 
Endometrial hyperplasia and tumor samples: in total 10 well differentiated tumor 
samples were stained for PR and CD44. from one representative sample hyperplasia 
as well as tumor was available. Paraffin embedded samples were obtained from the 
Erasmus University Medical Center Department of Pathology. 
The histopathologic diagnoses of all samples were reviewed by our pathologist, 
Patricia C Ewing, MD PhD. Descriptions of the samples are given in the Results section 
and in the Legends to the figures.
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Gene expression data analysis
All raw gene expression data have been posted at the GEO DataSets option in PubMed 
and are freely available to the scientific community. Raw data of both studies24-25 
were normalized as a group using RMA (Robust Multi-array Analysis) normalization26. 
from the Talbi data25 we only used gene expression data from well-characterized 
tissuesamples (Table 125 with the exception of samples 455 and 562 that were not 
made available to the GEO DataSets option in PubMed).  SAM (Statistical Analysis of 
Microarray) was performed in order to identify significant differentially regulated genes 
between different groups (E2, E2+MPA, PE, ESE, MSE, LSE) 
27. The median false discovery 
rate was set to 1% for these comparisons. Genes with differential expression due to 
difference in tissue source, rather than hormonal effects, were identified and excluded 
form subsequent analysis. Cluster analysis was performed as described by hanifi-
Moghaddam et al., 200724. Pathway analyses were conducted using ingenuity Pathway 
software (http://www.ingenuity.com).
Cell lines and transfections
ishikawa cell lines were maintained as described earlier28. During the transfection, 
infection and hormone stimulation experiments the cells were cultured in DMEM/
f12 supplemented with 5% dextran-coated charcoal-treated fetal calf serum in 
the presence of penicillin and streptomycin. Transfection was performed 24h after 
seeding of the cells (5000 cells per well in a 24-well plate); and 4h after transfection 
hormones were added to the cells (concentrations are indicated with the figures). At 
48h after transfection the cells were harvested to perform reporter assays. The stably 
PR transfected cell lines used in the shRNA experiments were generated as described 
earlier28; transcient transfections were performed as described earlier29. The TOPflash 
and fOPflash vectors were obtained from Millipore (Upstate, Billerica, MA, USA). 
DKK1 expression vector (cloned in pcDNA3.1) was obtained from Dr x. he30, fOxO1 
expression vector (cloned in pcDNA3.1) was obtained from Dr J.J. Kim31 and the dnTCf4 
expression vector (cloned in pcDNA3.1) was a gift from Dr h. Clevers32. 
The production of Lentivirus and stable cell line generation was performed as 
described before33. The shRNA  specific for hDKK1 (n = 5) and hfOxO1 (n = 6), non-target 
shRNA control vector, and TurboGfP control vector were obtained from The MiSSiON™ 
TRC shRNA libraries from Sigma-Aldrich (St. Louis, MO, USA). The packaging plasmids 
were provided by the Naldini lab, vita-Salute San Raffaele Univerity, Milan, italy. 
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immunohistochemistry and Western Blotting
immunohistochemistry and westernblotting was performed essentially as described 
before1,29. The dilutions of antibody used in immunohitochemistry were: Rat monoclonal 
CD44 antibody 1:1000 (BD Pharmingen, San Diego, CA, USA); Rabbit monoclonal 
ß-catenin antibody 1:4000 (Epitomics, Burlingame, CA, USA); Mouse PR antibody 1:50 
(Ab-8 cocktail, Neomarkers, fremont, CA). The dilutions in Western Blotting were: 
goat anti-hDKK1 antibody 1:500 (Af1096, R&D Systems, Minneapolis, MN, USA)); 
rabbit polyclonal anti-hfOxO1 antibody 1:5000 (A300-297A, Bethyl Laboratories, 
Montgomery, Tx, USA); rabbit anti-ß-Tubulin 1:1000 (Ab6046, Abcam, Cambridge, UK). 
RESULTS
Progestagens inhibit estrogen signaling during the regular
menstrual cycle
Significant Analysis of Microarrays (SAM-analysis) between the endometrial 
gene expression profiles obtained from untreated postmenopausal women in 
comparison to women treated for 21 days with E2 (estradiol) or E2 + MPA (estradiol + 
MedroxyProgesterone Acetate) indicated that 5932 probesets (representing 
approximately 4500 genes) were significantly up- or down-regulated (p < 0.00015)
Cluster analysis of these significantly up- or down-regulated genes reveals three 
distinct dendrogram branches: one cluster encompassed all endometrial gene 
expression profiles from E2-treated women, the second contained profiles from 
untreated controls, and the third profiles from both E2+MPA-treated women and 
untreated controls (fig. 1a). Ten genes were investigated using quantitative real time 
RT-PCR in a previous study to validate differential expression24. in figure 1b, highly E2 
regulated genes are shown to be counteracted (compensated for) by the addition of 
MPA. in total, 438 genes were identified as being significantly E2 regulated i.e. by more 
than 3-fold up- or down-regulated (fig 1b, closed bars). for 377 (233 + 144) of these 
genes, this E2-regulation was counteracted (compensated for), either in part, or fully, 
by simultaneous MPA administration (fig 1b, open bars). These analysis show that 
treatment with E2 alone has a profound impact on endometrial gene expression, and 
that this effect is greatly diminished upon addition of MPA to the E2 treatment.
We next integrated our profiling results with previously published gene expression 
data obtained during the main phases of the normal menstrual cycle25. SAM analysis 
revealed a total of 11866 probe sets (representing approximately 9000 genes) 
354
Figure 1. Steroid hormone regulation of endometrial gene expression. A: Cluster analysis of endometrial 
gene expression profiles obtained from postmenopausal women after no treatment (Con), 21-day treatment 
with E2, or E2 + MPA. Using statistical analysis (SAM), it was established that 5932 probesets (representing 
approximately 4500 genes) were significantly regulated between the three groups. At the bottom of figure 
1A relatedness is indicated. Red indicates genes with a higher expression relative to the geometrical means, 
while blue indicates genes with a lower expression relative to the geometrical means. B: Number of genes 
(# regulated genes) that were regulated at least 3-fold by E2 treatment (438 genes, closed bar) were also 
assessed in the E2 + MPA treatment group (open bars). Not comp: addition of MPA to E2 did not result in a 
change in the expression levels of these E2 regulated genes. Partly comp: addition of MPA to E2 resulted in 
a partial compensation (between 1- and 3-fold) of the expression levels of these E2 regulated genes. fully 
comp: addition of MPA to E2 resulted in a change in the expression of these E2 regulated genes back to 
the control levels (less than 1-fold regulated).  C: Cluster analyses of endometrial gene expression profiles 
obtained after 21-day treatment with either E2 or E2 + MPA, and during the proliferative endometrium (PE), 
early secretory endometrium (ESE), mid secretory endometrium (MSE), or late secretory endometrium 
(LSE) phases. Using statistical analysis (SAM), it was established that 11866 probesets (representing 
approximately 9000 genes) were significantly regulated between the three groups. At the bottom of the 
figure, relatedness and Clusters are indicated. Red indicates genes with a higher expression relative to the 
geometrical means, while blue indicates genes with a lower expression relative to the geometrical means.
355
significantly regulated between any of the six indicated groups (the E2 and E2+MPA 
treated endometria from the present study, and four different phases of the menstrual 
cycle; proliferative endometria (PE), early secretory endometria (ESE), mid-secretory 
endometria (MSE), late secretory endometria (LSE)25). These differentially expressed 
genes were employed for cluster analysis (fig. 1c). Three clusters were recognized, 
representing: Cluster 1) the samples from E2 treated patients and those from women in 
proliferative phase, Cluster 2) early- and mid-secretory phase specimens, and Cluster 3) 
the gene expression files from the E2+MPA treated patients and from women in late 
secretory phase. These results indicate that estradiol signaling is a very important factor 
during the proliferative phase of the menstrual cycle (fig. 1c, Cluster 1). furthermore, 
the addition of MPA to the estradiol treatment creates an endometrium with obvious 
similarities to the late secretory phase of the menstrual cycle (fig. 1c, Cluster 3). 
Progesterone inhibition of Wnt/β-catenin signaling involves 
both DKK1 and fOxO1
The gene expression data from figure 1C were subsequently used in a pathway 
analysis (http://www.ingenuity.com). it was observed that a number of pathways 
were significantly regulated by one of the treatments or in different phases of the 
menstrual cycle. for example, when we compared the proliferative endometrium to 
the early or mid-secretory endometrium,  “cancer”, “reproductive system disease” and 
“gastrointestinal disease” were all significantly regulated (p<0.006). it is interesting to 
note that “gastrointestinal disease” and “cancer” both were found to be significantly 
regulated, which could point to involvement of Wnt/β-catenin signaling. Upon 
assessing the involvement of “canonical pathways” it was found that “Wnt/β-catenin 
signaling” was also significantly regulated (p< 0.003) in both the early and the mid-
secretory endometrium compared to the proliferative endometrium. 
Because of our interest in the Wnt/β-catenin signaling pathway we decided to 
perform a more thorough pathway analysis for either downstream targets or integral 
parts of the Wnt/β-catenin signaling pathway (http://www.stanford.edu/~rnusse/
wntwindow.html34-35) (Supplementary Table 1). Upon performing this analysis, a large 
number of differentially expressed genes (n=228) were recognized. Because our 
investigations center on the mechanism through which progesterone counteracts the 
proliferative effects of estradiol during the menstrual cycle and during early endometrial 
carcinogenesis, we have focused on the progesterone-induced Wnt/β-catenin signal-
inhibitor DKK136 and the alleged inhibitor fOxO137-38 (fig. 2). 
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Figure 2. Endometrial expression of DKK1 (black bars) and fOxO1 (gray bars) during steroid hormone 
treatment (Con, E2 and E2+MPA) and during the menstrual cycle. Microarray data of DKK1 and fOxO1 
are plotted. The fOxO1 data represent the average of the data obtained from 4 different probesets (see 
Supplementary Table 1). On the Y-axis the normalized expression levels are indicated, on the x-axis the 
different experimental groups are indicated. Con = non treated, E2 = Estradiol treated (21 days), E2 + MPA 
= Estradiol + MedroxyProgesterone Acetate treated (21 days), PE = proliferative endometrium, ESE = early 
secretory endometrium, MSE = mid secretory endometrium, LSE = late secretory endometrium (Con, E2 and 
E2+MPA data are from 24; PE, ESE, MSE and LSE data are from 25). Differences between Con and hormone 
treatments were considered significant (*) when p < 0.05. Differences between PE treatment and other stages 
of the menstrual cycle were considered significant (**) when p < 0.05.
in order to investigate the molecular mechanisms underlying progesterone-driven 
inhibition of Wnt/β-catenin signaling, we employed the well differentiated ishikawa 
endometrial cancer cell line39. As shown in figure 3a, TOP/fOPflash reporter assay 
analysis indicates that Wnt/β-catenin signaling is constitutively active in ishikawa cells. 
furthermore, we could clearly show that Wnt/β-catenin signaling is inhibited upon MPA 
treatment (fig. 3a). The concentration of MPA necessary to fully inhibit Wnt/β-catenin 
signaling is approximately 0.1 nM and this is close to the reported dissociation constant 
for both progesterone receptor isoforms40. Using this ligand concentration (0.1 nM), 
molecular excess of the antiprogestagen Org-31489 could fully reverse Wnt/β-catenin 
signaling inhibition. furthermore, it was shown that both activated progesterone 
receptors (PRA and PRB) could inhibit Wnt/β-catenin signaling, although PRB did so at 
lower MPA concentrations (Supplementary figure 1).
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Figure 3. Progesterone, DKK1 and fOxO1 inhibit Wnt/β-catenin signaling in ishikawa cells. ishikawa cells 
were transfected with the TOP-fLASh Wnt/β-catenin reporter construct and several other constructs as 
indicated in the figure (plasmids are depicted in nanogrammes per well of a 24-well culture plate). 
furthermore, the cells were cultured for 48h in the presence or absence of MPA or the antiprogestagen Org-
31489 (amounts are indicated in the figure41). dnTCf represents a dominant negative inhibitor of Wnt 
signaling32. All experiments are corrected for transfection efficiency by using the tk-renilla vector. The 
experiments performed under A, B and C have all been repeated at least three times and are independently 
performed from each other. Differences between non treated and treatments and/or transfections were 
considered significant (*) when p < 0.05.
As shown in figure 2, the expression of the Wnt/β-catenin signaling inhibitors DKK1 
and fOxO1 is elevated during the early secretory phase of the menstrual cycle, peaks 
during the mid secretory phase and declines during the late secretory phase (fig. 2). 
furthermore, for DKK1 direct progesterone receptor activation of the promoter region 
was measured (Supplementary fig. 2). These findings could indicate that progesterone 
inhibits Wnt signaling by inducing the expression of DKK1 and fOxO1 during the early 
and mid secretory phase of the menstrual cycle. As shown in figure 3b, transfection 
of ishikawa cells with increasing amounts of DKK1 or fOxO1 expression vector (30ng, 
100ng and 300ng per well) results in the progressive inhibition of Wnt/β-catenin 
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signaling. When cells were transfected with DKK1 or fOxO1 in the presence of MPA 
(fig. 3c), or with both DKK1 and fOxO1 together, Wnt/β-catenin signaling inhibition 
was even more pronounced. Notably, inhibition of Wnt/β-catenin signaling by DKK1 
and fOxO1 together was comparable to inhibition by the strong dominant negative 
expression vector dnTCf132. 
in order to further substantiate that induction of DKK1 and fOxO1 by progesterone 
is central to inhibition of Wnt/β-catenin signaling, expression of both DKK1 and fOxO1 
was reduced by the use of lentiviral sequence-specific short hairpin RNAs. five DKK1 
and 6 fOxO1 targeting lentivirusses were employed to infect ishikawa cells. As shown in 
figure 4a, partial inhibition of progesterone induction of DKK1 and fOxO1 expression 
was achieved by infection with combinations of all available specific DKK1 or fOxO1 
shRNAs. Based on these results, ishikawa cells infected with either DKK1- or fOxO1-
specific shRNAs were then used to measure progesterone inhibition of Wnt signaling. 
MPA inhibition of TOP-fLASh Wnt/β-catenin reporter system was partly circumvented 
by the lentiviral shRNAs directed against DKK1 and fOxO1 (fig. 4b). furthermore, 
prevention of MPA activity was observed when DKK1 and fOxO1 shRNAs were 
combined. in conclusion, progesterone-induced upregulation of DKK1 and fOxO1 is 
responsible, in part, for Wnt/β-catenin signaling inhibition in the endometrium.
Progesterone inhibition of Wnt/β-catenin signaling in normal 
endometrium and endometrial cancer. 
it has been reported that at least 30% of early estrogen-associated tumors (Type 
i endometrioid) display the hallmark of Wnt signaling activation, namely nuclear 
β-catenin accumulation9,13. We performed immunohistochemistry on histological 
sections from 10 well-differentiated endometrium carcinomas, and three of these 
showed nuclear β-catenin staining (fig. 5a, left panel). To confirm that intracellular 
β-catenin accumulation was accompanied by upregulation of known Wnt/β-catenin 
downstream targets, CD44 immunohistochemistry analysis was also performed on 
these three nuclear β-catenin positive tumors42. As shown in figure 5a, CD44 expression 
coincides very well with nuclear β-catenin accumulation. Moreover, in regions where 
β-catenin staining is present but not nuclear, CD44 staining is undetectable (fig. 5a, 
arrowheads). 
in agreement with our hypothesis that estradiol induces Wnt/β-catenin signaling 
to trigger proliferation of the endometrium, it was observed that expression of the 
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Wnt target gene CD44 in the endometrium of the seven E2 treated women was higher 
than in the six E2+MPA treated women (fig. 5b). furthermore, when CD44 expression 
was measured during hyperplasia, CD44 expression became markedly reduced upon 
treatment with progestagens (supplementary fig. 3). 
Figure 4. inhibition of DKK1 and fOxO1 expression partly circumvents MPA inhibition of Wnt/β-catenin 
signaling. A: Activity of shRNAs directed against DKK1 or fOxO1 were tested in PR expressing ishikawa cells. 
B: ishikawa cells infected with shRNA were transiently transfected with PRA, PRB and the TOP-fLASh Wnt/β-
catenin reporter system. The hatched bars indicate MPA inhibition of Wnt/β-catenin reporter activity in the 
presence of Control (shCon), DKK1 (shDKK1) and/or fOxO1 (shfOxO1) shRNAs. All experiments are corrected 
for transfection efficiency by using the tk-renilla vector. Differences between MPA treatment and non treated 
or shRNA treated were considered significant (*) when p < 0.05.
This particular patient underwent hysterectomy because of the development of a 
well differentiated endometrial carcinoma. immunohistochemical staining for CD44 in 
this tumor showed a heterogeneous staining pattern. in some fields it was clear that 
staining for CD44 was positive in areas of carcinoma while adjacent areas of hyperplasia 
were negative (fig. 6a). Endometrial tumors often progress to become progestagen-
independent and therefore progesterone receptor expression was also assessed by 
immunohistochemistry and compared with CD44 staining (fig. 6b). Epithelial CD44 
staining was minimal in areas where expression of the progesterone receptor was 
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Figure 5. Wnt/β-catenin signaling in different endometrial samples. A: β-catenin and CD44 staining of an 
area of endometrial hyperplasia in a uterus containing a well-differentaited adenocarcinoma. Arrowheads 
indicate a region with cytoplasmic β-catenin staining which is devoid of CD44 staining. The higher power 
shows a squamous morule, where it is recognized that nuclear β-catenin staining is particularly intense 43. 
CD44 also stains intensely in this area. B: CD44 staining of  the endometrium after 21 days of E2, or E2 + MPA 
treatment1.
 
Figure 6. Progesterone regulation of Wnt/β-catenin signaling in endometrial cancer. A: Overview of CD44 
staining of endometrial carcinoma during progestagen treatment (approximately 40-fold magnification). B 
Detail (approximately 200-fold magnification) of staining of endometrial carcinoma for CD44 and 
progesterone receptors A and B during progestagen treatment. The images on the left are from an area of 
complex cribriform growth representing adenocarcinoma. The images on the right are from an area where 
the morphology is still that of hyperplasia. C: synopsis of the findings presented in B: in those regions where 
progesterone signaling is active (PR-positive), epithelial CD44 staining is reduced and Wnt/β-catenin 
signaling is inhibited. in those regions that have become progesterone-insensitive (PR-negative), CD44 
staining is enhanced and Wnt/β-catenin signaling is no longer inhibited.
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positive (fig 6b, closed arrows). Conversely in regions devoid of progesterone receptor 
signaling, CD44 levels were clearly enhanced (fig 6b, open arrows). in order to further 
substantiate our findings, we reviewed 10 cases of well differentiated endometrial 
cancer. in all these cases, when the progesterone receptor was present, CD44 levels 
were low or undetectable, and in those regions of the tumor where the progesterone 
receptor was lost, CD44 expression was high (supplementary fig. 4). These data suggest 
that Wnt/β-catenin signaling can be inhibited by progesterone in estrogen-associated 
endometrial hyperplasia and cancer, but only in the presence of progesterone receptors 
(fig. 5 and 6). 
 
DiSCUSSiON
Sustained or unopposed estrogen signaling in the endometrium results in hyperplasia44, 
which is followed in approximately 25% of cases by tumor formation2. Two groups of 
women are known to be at high-risk for endometrial cancer because of sustained or 
unopposed estrogen-like activity: those who are significantly overweight45 (relative risk 
> 4) and those receiving tamoxifen (a partial oestrogen antagonist) for breast cancer 
treatment46 (5 year usage relative risk > 7). it has been estimated that up to 40% of all 
endometrial cancers may be related to obesity, a figure that is rising as the prevalence 
of obesity increases. 
it has been reported that at least 30% of these early estrogen-associated tumors 
(Type i endometrioid) display the hallmark of Wnt/β-catenin signaling activation, namely 
nuclear β-catenin accumulation9,13, suggesting a cause-effect relationship between 
sustained estrogen signaling and aberrant Wnt/β-catenin signaling. Accordingly, we 
found a significant number of targets and components of the Wnt/β-catenin signaling 
pathway among the genes differentially regulated in the endometrium of E2 treated 
women (Supplementary Table 1). This is indicative of the impact of estrogen signaling 
on this pathway. for example, the Wnt/β-catenin signaling target iGf-1, regarded as 
one of the most important endometrial growth factors47, was found to be strongly up-
regulated (12-fold) by estradiol and inhibited after the addition of progesterone. in 
literature there are also a number of reports implicating progesterone and estradiol in 
regulation of Wnt/β-catenin signaling in the endometrium. Cloke et al.48 for example, 
showed that knockdown of the progesterone receptor resulted in activation of Wnt/β-
catenin signaling in differentiating human endometrial stromal cells. in agreement 
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with this, Satterfield49 could show that progestagens, administered to pregnant sheep 
induced a transient decline in Wnt/β-catenin signaling activity. Seemingly in contrast 
to these finding, Rider50 showed that estrogens activated Wnt/β-catenin signaling in 
stromal cells, but only after initiation by progestagens. finally, Katayama51 showed 
that administration of an estrogen agonist to immature female rats resulted in down 
regulation of Wnt7A, and up-regulation of Wnt4 in the uterus, while Catalano52 showed 
upregulation of Wnt5A in the endometrium by antiprogestagen treatment in healthy 
volunteers. These reports and our own observations led us to hypothesize that Wnt/β-
catenin signaling is stimulated by estrogens and inhibited by  progestagens during the 
menstrual cycle. 
in order to investigate steroid regulation of Wnt signaling during the menstrual 
cycle, the possible involvement of the progesterone-induced Wnt/β-catenin signaling 
inhibitors DKK1 and fOxO1 was investigated by use of the well differentiated endometrial 
cancer cell line ishikawa. for DKK1 there is good evidence that this protein can bind 
to the Wnt co-receptors LRP5 and LRP6, thus inhibiting Wnt/β-catenin signaling53. 
for fOxO1 the evidence is scarcer. Essers et al.54 reported that fOxO1 directly binds 
to β-catenin and Almelda et al.37 could show that this binding results in inhibition of 
Wnt/β-catenin signaling. in the endometrial cancer cell line ishikawa, where we could 
show that Wnt/β-catenin signaling was constitutively active, progesterone effectively 
inhibited Wnt/β-catenin reporter activity (fig. 3a). furthermore, upon progesterone 
treatment there was upregulation of DKK1 and fOxO1 expression (fig. 4 and31), an 
observation in keeping with the profound up-regulation of the expression of both genes 
during the secretory phase of the menstrual cycle (fig. 2 and20). interestingly, Tulac et 
al.20, but also Kane et al55, show progesterone induced DKK1 expression specifically in 
stromal cells of the endometrium. in analogy to Wnt5A, which is produced by stromal 
cells and acts on uterine glands18, it is possible that stroma-produced DKK1 is specifically 
important to inhibit Wnt/β-catenin signaling in glandular and luminal epithelial cells of 
the endometrium. The fact that here we are using a well differentiated endometrial 
cancer cell line of epithelial origin, which shows progesterone induction of DKK1, on 
the one hand does not represent the physiological situation of the menstrual cycle, 
but on the other hand does allow us to dissect out the role of progesterone in Wnt/β-
catenin signaling regulation. 
Upon transfection of ishikawa cells with vectors encoding either DKK1 or fOxO1, 
Wnt/β-catenin signaling was clearly inhibited thus indicating that both proteins can 
serve as Wnt/β-catenin signal inhibitors in response to progesterone. indeed, inhibition 
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of Wnt/β-catenin signaling by progesterone treatment was partly circumvented by 
shRNA-driven down-regulation of DKK1 or fOxO1 expression. 
By using the Wnt/β-catenin downstream target CD44 as a marker for Wnt signaling, 
it was shown that E2 treatment seems to result in enhanced Wnt/β-catenin signaling. 
CD44, hyaluronic acid receptor, in this respect is an interesting marker because it has 
been implicated in progression and metastasis of a number of different cancers56. E2 
induced CD44 expression was counteracted (compensated for) by MPA treatment 
(fig. 6b). furthermore, estrogen-induced endometrial hyperplasia44, also displayed 
increased CD44 expression which was shown to be inhibited by progestagen 
treatment (Supplementary fig. 3). Notably, in an endometrial carcinoma arising during 
treatment of endometrial hyperplasia with progestagen, areas with enhanced Wnt/β-
catenin signaling (CD44 positive) generally corresponded to areas of carcinoma while 
regions that displayed reduced Wnt/β-catenin signaling (CD44 negative) tended to 
correspond to areas with the morphology of hyperplasia. Staining the same regions 
for progesterone receptor expression indicated that the presence of progesterone 
receptors correlated with a decrease in Wnt/β-catenin signaling whereas its absence 
coincided with enhanced Wnt/β-catenin signaling. Similar observation were done in 
other well differentiated endometrial tumors (Supplementary fig. 4) and several years 
ago by hanekamp, who could also show a clear correlation between the absence of PRs 
and the presence of CD4457. 
in endometrial hyperplasia and cancer we have thus observed that when 
progesterone receptor signaling is intact, progesterone indeed seems to be able to 
inhibit Wnt signaling (inhibit CD44 expression). This inhibitory effect of progesterone 
most likely limits cancer progression, which is observed in 15-25% of patients with 
metastatic endometrial cancer who respond to progesterone therapy3,58. Progesterone 
treatment, however, only renders a temporary relief and the disease often becomes 
progesterone-insensitive58. Based on the findings of the present study, it seems 
warranted to consider treatment of endometrial cancer patients whose disease has 
become progesterone resistant with inhibitors of the Wnt/β-catenin signaling  pathway59 
that are acting down-stream of progesterone signaling. Endostatin has been shown 
to inhibit Wnt/β-catenin signaling through inhibition of LEf160. LEf1 is an important 
part of the Wnt/β-catenin pathway which we have shown to be up-regulated by 
estrogens during the proliferative phase of the menstrual cycle and down-regulated 
by progestagens during the secretory phase of the menstrual cycle25 (Supplementary 
Table 1). Endostatin may thus be a potential therapeutic option in progesterone 
insensitive metastatic endometrial cancer. 
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in summary, our results provide support for the hypothesis that during the pro-
liferative phase of the menstrual cycle increased estradiol levels induce Wnt/β-catenin 
signaling to enhance proliferation, while during the secretory phase progesterone 
levels inhibit Wnt/β-catenin signaling thereby counterbalancing estradiol-induced 
proliferation and enhancing differentiation.  furthermore, progesterone also seems 
to be able to inhibit Wnt/β-catenin signaling during endometrial carcinogenesis 
thus inhibiting the disease. in addition, we provide mechanistic evidence that the 
Wnt/β-catenin signaling inhibitors DKK1 and fOxO1 are acting down-stream of the 
progesterone receptor to trigger inhibition of Wnt/β-catenin signaling. 
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cyclin D1. J Biol Chem. 2002;277:16464-16469.Progesterone inhibition of Wnt/β-catenin signaling in ishikawa cells 
transfected with PRA, PRB or both progesterone
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Supplementary Figure 1. Progesterone inhibition of Wnt/β-catenin signaling in ishikawa cells transfected 
with PRA, PRB or both progesterone receptors. ishikawa cells were transfected with the TOP-fLASh Wnt/β-
catenin reporter construct and either PRA, PRB orboth progesterone receptors (30 ng/well). furthermore, the 
cells were cultured for 48h in the presence or absence of MPA (amounts are indicated in the figure) All figure). 
experiments are corrected for transfection efficiency by using the tk-renilla vector. The experiments have all 
been repeated at least three times. The error bars represent the standard deviation of three transfections 
within one experiment. 
Supplementary Figure 2. MPA induction of DKK1 promoter-luciferase reporter constructs. ishikawa cells 
were transfected with PRA and PRB, the progesterone inducible construct MMTv-luciferase (MMTv) and two 
different DKK1-promotorluciferase reporter constructs (DKK1 -2238/+112 and DKK1 -321/+112). The cells 
were subsequently cultured in the presence or absence of MPA (1nM) for 48h before harvest and measurement 
of luciferase activity. All experiment are corrected for transfection efficiency by using the tk-renilla vector.
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Supplementary Figure 3. CD44 staining of endometrial hyperplasia before (pretreatment) or after (during 
MPA treatment) progestagen treatment (approximately 200-fold magnification).
Supplementary Figure 4. Progesterone regulation of Wnt/β-catenin signaling in 7 different endometrial 
cancer samples. Details (approximately 40-fold magnification) of staining of endometrial carcinoma for CD44 
(right) and progesterone receptors A and B (left). in those regions where progesterone signaling is active 
(PRpositive), epithelial CD44 staining is reduced; in those regions that have become progesterone-insensitive 
(PR-negative), CD44 staining is enhanced.
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SUPPLEMENTARY TABLE 1
Endometrial gene expression data from hormone treated postmenopausal women and 
from women during different stages of the menstrual cycle. The genes are indicated on 







Expression of Wnt/β-catenin pathway targets and components during steroid hormone treatment and 
during the menstrual cycle. Microarray data of a number of relevant Wnt/β-catenin pathway components 
and targets detected by specific probesets are plotted. for some genes more probesets were available, 
and therefore more sets of data are plotted in one figure (different colours). On the y-axis the normalized 
expression levels x 1000 are indicated, on the x-axis the different experimental groups are indicated: 1= 
non treated, 2= E2 treated, 3= E2 + MPA treated (present data for postmenopausal 21-day steroid hormone 
treated patients), a= proliferative endometrium, b = early secretory endometrium, c = mid secretory 
endometrium, d = late secretory endometrium (data from (Talbi, 2006)
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in fertile women, the endometrium undergoes regular cycles of tissue build-up and 
regression. it is likely that uterine stem cells are involved in this remarkable turn over. 
The main goal of our current investigations was to identify (quiescent) endometrial stem 
cells by means of a pulse-chase approach to selectively earmark, prospectively isolate, 
and characterize label-retaining cells (LRCs). To this aim, transgenic mice expressing the 
fusion protein histone 2B - GfP (h2B-GfP) in a Tet-inducible fashion were employed. 
After 7 days of doxycycline treatment (pulse), the doxycycline water was replaced 
by normal water (chase). Over time, dividing cells progressively loose the GfP signal 
after each mitosis, whereas quiescent (infrequently dividing) cells will retain h2B-GfP 
expression. We evaluated h2B-GfP retaining cells at different chase time points and 
identified long-term (>12 weeks) LRCs. These LT-LRCs do not express estrogen receptors 
and a low level of progesterone receptors (ER- and PR-), which is reminiscent of stem 
cells in other hormone-regulated organs such as the mammary gland. fACSorted LRCs 
are able to form spheroids capable of self-renewal and differentiation. Under serum 
stimulation spheroid cells can form glandular structures in vitro which express markers 
of mature Műllerian epithelial cells. in summary, it is shown that quiescent cells located 
in the distal oviduct have stem-like properties and can differentiate into distinct cell 
lineages specific of endometrium, proximal and distal oviduct. future lineage-tracing 
studies will be needed to elucidate the role played by these cells in homeostasis, tissue 
injury and cancer of the female reproductive tract in the mouse and eventually in man. 
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iNTRODUCTiON
Stem cells are relatively undifferentiated and naive cells endorsed with the ability to 
self-renew and to give rise to committed progenitors and eventually to differentiated 
cell lineages. Somatic stem cell niches such as skin1-4, mammary gland5, stomach6, 7, 
and bone marrow8, 9 have been shown to encompass both quiescent and cycling 
populations. Whereas cycling stem cells maintain daily homeostasis, their quiescent 
equivalents have been postulated to play a rate-limiting role in tissue regeneration 
upon injury10, 11. To date, very little is known about the nature and localization of stem 
cells in the female reproductive tract and in particular in the uterus12. 
The very first evidence for the existence of a stem cell population in the endometrium 
came by plating out single endometrial cells in vitro to assay their clonogenicity. it was 
observed that 0.08% of epithelial and 0.02% of stromal cells formed large colonies 
which could be passaged several times13. furthermore, passaging of epithelial colonies 
in matrigel resulted in large cytokeratin expressing gland-like structures14. Additional 
studies on the identification of endometrial stem cells indicated that, in bone-
marrow transplanted patients, donor-derived bone marrow cells could be found in 
the endometrial epithelium (0.2 – 48% of cells) and stroma (0.3 – 52% of cells)15. This 
observation was confirmed in lethally irradiated female mice transplanted with bone 
marrow from male donors: more than 0.5% of the epithelial endometrial cells were 
shown to be donor-derived16, 17. 
Bromodeoxyuridine (BrdU) label retention also was employed to identify 
infrequently dividing cells in the endometrium, a feature of stem cells: after 8 weeks of 
chase approximately 3% of endometrial epithelial cells still retained the BrdU label18. 
After 12 weeks of chase, however, no label-retaining cells (LRCs) were present in the 
luminal and glandular epithelium, whereas few stromal BrdU-positive cells were 
observed at the endometrial-myometrial junction in close proximity to the blood 
vessels. however, DNA-labeling by BrdU is dependent on cell division and in itself 
represents a genotoxic insult for quiescent stem cells, thus triggering their cell cycle 
activation8. here, we have employed a non-mutagenic and cell cycle independent 
approach, namely in vivo pulse-chase with the histone 2B - green fluorescent protein 
(h2B-GfP)1, 8, 9, towards the identification and prospective isolation of long-term LRCs 
(LT-LRCs) in the mouse female reproductive tract. We show that ex-vivo culture of LT-
LRCs sorted from the distal oviduct gives rise to undifferentiated spheroids which 
display self-renewal capacity and can be induced to differentiate into cells resembling 




Transgenic hNRPA2B1/rtTA2S-M2 (rtTA) mice19 were bred with tetO-hiST1h2BJ/GfP 
(h2BGfP) mice1 (kindly provided by Elaine fuchs, New York). Young adult (8 – 12 weeks 
of age) compound heterozygous rtTA/h2BGfP transgenic mice and control littermates 
were administered doxycycline (Sigma, Zwijndrecht, the Netherlands) at 2 mg/ml in 
5% sucrose containing drinking water for 7 days (pulse). Doxycycline-containing water 
was protected from light and refreshed every 2 days. After doxycycline treatment, 
doxycycline-containing water was replaced by normal water (chase). GfP expression 
in mice was analyzed at various time points after doxycycline treatment, from 0 till 47 
weeks. All experiments conducted with mice were approved by local animal ethics 
committee (DEC permit numbers EUR1494 and EUR1785) and were in accordance to 
international guidelines and regulations.
Antibodies and chemicals 
Primary antibodies were: biotinylated anti-mouse CD31 (BD, Breda, the Netherlands), 
biotinylated anti-mouse CD45 (BD), biotinylated anti-mouse TER-119 (BD), anti-CD44 
(PE) (BD), rabbit anti-GfP (invitrogen, Breda, the Netherlands), mouse anti-GfP (Roche, 
Woerden, the Netherlands), anti-PR (DAKO, Enschede, the Netherlands), anti-β-catenin 
(Epitomics, Burlingame, USA), anti-ERalpha (Millipore, Amsterdam, the Netherlands), 
anti-Keratin 8 (Covance, Uden, the Netherlands), anti- Ki67 (Monosan, Uden, the 
Netherlands), anti-PAEP (Sigma).
Second antibodies were: rabbit/mouse Envision (DAKO), anti-rabbit 
immunoglobulins/biotinylated (DAKO), anti-mouse immunoglobulins/biotinylated 
(DAKO), anti-rat immunoglobulins/biotinylated (DAKO), anti-goat immunoglobulins/
biotinylated (DAKO), anti-rat Alexa fluor 633 (invitrogen), anti-rat Alexa fluor Cy3 
(invitrogen), anti-mouse Alexa fluor 488, 594 (invitrogen), anti-rabbit Alexa fluor 
594 (invitrogen), fluorescent anti-rabbit (invitrogen), Strepavidin-PerCP-Cy5.5 (BD), 
Streptavidin peroxidase (BioGenex, Duiven, the Netherlands). for nuclear staining, 
the following were employed: hoechst 33342, 34580 (invitrogen), DAPi (invitrogen), 
DRAQ5 (Biostatus, Leicestershire, UK).
Employed chemicals and biologicals included: PBS (invitrogen), Matrigel Matrix (BD), 
DMEM/f12 (invitrogen), Antibiotic/Antimycotic (invitrogen), Gentamycin (invitrogen), 
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Recombinant Mouse EGf (invitrogen), Recombinant mouse bfGf (invitrogen), B27 
(invitrogen), DNAse (Sigma), Collagenase (Sigma), TrypLE express (invitrogen), Triton 
(Sigma), formaldehyde (Merck, Schiphol-Rijk, the Netherlands), Select Agar (invitrogen).
flow cytometry 
The oviducts of mice chased for 12 weeks were mechanically (Stomacher® 80 
microBiomaster, Seward Limited, West Sussex, UK) and enzymatically dissociated in 
medium containing 3 mg/ml Collagenase (Sigma) and 50 µg/ml DNAse (Sigma) at 37°C, 
in a 5% CO2 incubator for 30 minutes in order to obtain a single cell suspension. To 
remove debris, the cell suspension was washed in PBS and passed through a 40 µm 
cell strainer (BD). To exclude non-epithelial cells from analysis, cells were stained for 
different lineage markers with primary antibodies directed against CD31, CD45 and 
TER-119, and Strepavidin-PerCP-Cy5.5 as a secondary antibody. Cells were incubated 
with 0.2 μg/ml hoechst-33342 in PBS for 5 minutes to discriminate live from dead cells. 
Live cells were sorted for high (GfP+) or very low GfP expression (GfP-negative) by 
using a fACSAria (BD) flow sorter.
in vitro cell culture and differentiation assay 
After sorting, the cells were washed in cold PBS, re-suspended in Matrigel, seeded in 
24-well plates (Corning B.v, Amsterdam, the Netherlands), and subsequently covered 
with culture medium. The culture medium consisted of DMEM/f12 supplemented with 
1% v/v B27, 20ng/ml bfGf, 20ng/ml EGf, 100µg/ml Gentamycin in the presence of 
antibiotics and antimycotics. The medium was refreshed every two days. 
for the single cell self-renewal assay, fACSorted GfP+ and GfP-negative cells were 
allowed to form spheroids for 20 days. Subsequently, the spheroids were washed in 
cold culture medium and digested in TrypLE express medium for 5 minutes at 37°C, in a 
5% CO2 incubator. The resulting single cell suspension was microscopically evaluated, 
washed in culture medium, resuspended in Matrigel, seeded in a 24-well plate, covered 
with culture medium, and allowed to form spheroids again. After 20 days this protocol 
was repeated to again obtain single cells which formed spheroids in culture. 
in order to obtain detailed microscopic images of the spheroids, 1 nm doxycycline 
was used to induce GfP expression in all cells and facilitate their visualization. images 
were captured by confocal microscopy LSM510 (Zeiss, Göttingen, Germany). Three-
dimensional reconstruction was performed using the LSM510 software (Zeiss) and 
Amira (visage, Berlin, Germany) software packages.
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for the differentiation assay, spheroids cultured for five weeks were employed. The 
spheroids were re-suspended in cold culture medium and plated in tissue culture coated 
24-well plates. After 4 hours of culture at 5% CO2 at 37°C, the medium was carefully 
removed, and a drop of Matrigel was placed on the top of the spheroids. Subsequently, 
culture medium supplemented with 10% fCS was added to the Matrigel covering the 
spheroids to stimulate differentiation. Morphology changes were recorded by confocal 
microscopy. 
histology and image analysis 
histological analyses were performed on whole mount spheroids and paraffin-
embedded sections of spheroids and mouse tissues. for whole mount staining, the 
spheroids growing in Matrigel were fixed and permeabilized with 4% formaldyhyde 
and 1% Triton for 1.5 hours at room temperature, and incubated for 30 minutes with 
blocking solution (3% BSA; 0.1% Triton). Primary antibodies diluted in blocking solution 
were then incubated o/n, followed by incubation with the appropriate secondary 
antibody and subsequent substrate incubation. 
To embed morphologically intact spheroids in paraffin, they were first fixed in 4% 
formaldehyde at 37°C for 2 hours before being transferred to fresh 4% formaldehyde 
at 4°C overnight. Subsequently, fixed spheroids were transferred into 5% Select Agar 
which was embedded in paraffin to support sectioning. 
immunohistochemical staining for ER, PR, Ki67, CD44, GfP, PAEP, CK8 and beta-catenin 
was performed as described before20. for the double fluorescent staining of ER, PR, 
Ki67, CD44 and GfP, the primary antibodies were added simultaneously. The second 
antibodies were chosen based on the primary antibodies. Nuclei were stained with 
hoechst 34580, DAPi or DRAQ5. 
The images were acquired by using Axioplan 2 (Zeiss), Olympus Bx41 (Olympus, 
hamburg, Germany) and Nanozoomer Digital Pathology (NDP) (hamamatsu Photonics 
Deutschland Gmbh, herrsching, Germany). 
RESULTS 
identification and characterization of LT-LRCs in the distal 
oviduct 
To investigate the origin of stem-like cells in the female reproductive tract, we employed 
a mouse model that allows the identification and prospective isolation of label-
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retaining cells in a non-mutagenic and cell cycle independent fashion, namely with 
histone 2B - green fluorescent protein (h2B-GfP) as label1, 8, 9. To this aim, hNRPA2B1/
rtTA2S-M219 (rtTA) mice were bred with tetO-hiST1h2BJ/GfP (h2B-GfP) mice1 and 
compound heterozygous animals were treated for 7 days by doxycycline administration 
in drinking water to induce expression of the h2B-GfP label (pulse). h2B-GfP labeling 
of the vast majority of uterine cells was observed after 7 days of doxycycline pulse 
both by immunohistochemistry (ihC; fig. 1) and immunofluorescence (Supplementary 
fig. 1A, 0w). Notably, the h2B signal appears much higher in epithelial than in stromal 
or myometrial cells. in figure 1, ihC analysis of h2B-GfP after 7 days of doxycycline 
treatment shows clear and complete epithelial staining in the distal and proximal 
oviduct, and in the endometrium (fig. 1B-D; first column). Upon doxycycline withdrawal 
(chase), dividing cells progressively lose their h2B-GfP signal, while quiescent or 
infrequently dividing cells will retain the label for longer chase periods (fig. 1A). in the 
endometrium, epithelial cells appear to completely loose h2B-GfP expression within 
2 to 4 weeks (Supplementary fig. 1B-C, arrows point to LRCs), whereas stromal LRCs 
loose h2B-GfP expression between 8 and 12 weeks of chase (Supplementary fig. 1C, 
arrows point to LRCs). in the proximal oviduct no label retaining cells are retained after 
12 weeks of chase (fig. 1C). Remarkably however, many LRCs are observed after 12 
weeks of chase in the distal oviduct (fig. 1B, Supplementary fig 2). furthermore, after 
an extensive 47 week chase multiple LRCs are still present in the distal oviduct (fig. 
1B). here, we will refer to LRCs persisting for at least 12 weeks of chase and onwards, as 
long-term label-retaining cells (LT-LRCs). 
These results were confirmed by fACSorting of GfP+ cells from whole oviducts 
before pulse (untreated animals as negative controls) and at chase times 0, 12 and 47 
weeks (fig. 1E). Oviductal cells from untreated mice showed a very low GfP signal (black 
line). in contrast, after 1 week of dox-pulse (chase time 0 weeks, red line) a large portion 
of cells displayed a strong GfP signal. At increasing chase times, oviductal cells show 
substantial loss of their GfP signal (dark-green line; chase time 12 weeks), whereas after 
47 weeks of chase only very few GfP+ cells are present (fig. 1E, light-green line). Based 
on the above, all subsequent analyses were performed at 12 weeks of chase. 
To characterize the newly identified LT-LRCs in the distal oviduct, if analysis was 
performed for expression of estrogen and progesterone receptors, CD44, a stem cell 
marker in the mammary and other epithelial niches21, 22, and ki67 as an indicator of 
proliferative activity. in the mammary gland, epithelial cells are both estrogen and 
progesterone receptor positive, yet the stem cells do not express either receptors23-25. 
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Figure 1. Pulse-chase experiment using the doxycycline-inducible h2B-GfP system. A schematic 
representation of the experiment is given in A, where treatment with doxycycline results in expression of 
h2B-GfP throughout the entire body. At different chase points (12 weeks (12W) and 47 weeks (47W)), the 
GfP signal is progressively lost from dividing cells and retained in quiescent cells in the distal oviduct (B), 
the proximal oviduct (C) and the endometrium (D). fACSorting was performed on single cell digestions of 
oviducts from different mice. in the graph, the GfP signal is plotted against the number of cells. Animals used 
were: untreated mice as negative controls (black line), mice chased for 0 weeks as positive controls (red line), 
mice chased for 12 weeks (green line) and mice chased for 47 weeks (light-green line).
furthermore, the vast majority of the epithelial cells from the female reproductive 
tract are known to response to estrogen and progestagen hormones 26. Expression of 
estrogen receptor alpha (ERα) and progesterone receptors A and B (PR) was assessed 
in LT-LRCs (GfP+) after 12 weeks of chase. As shown in fig. 2A, LT-LRCs do not express 
ERα. furthermore, in contrast to the endometrium, the distal  oviduct displayed very 
low levels of PR expression (fig. 2B and Supplementary fig. 3) and, accordingly, LT-LRCs 
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appear negative for PR expression (fig. 2B). To validate the quiescent  nature of LT-LRCs, 
expression of the proliferation marker Ki67 was also evaluated. Overall, very few ki67-
positive cells were observed in the distal oviduct and, accordingly, double positive cells for 
GfP and Ki67 were never observed (fig. 2C and Supplementary fig. 4). As for CD44, many 
cells throughout the distal oviduct were positive, though never in GfP+ cells (fig. 2D). 
Notably, double staining analysis revealed that most CD44-expressing cells also 
expressed ERα (fig. 2E). 
Overall, these data indicate that a cluster of epithelial LT-LRCs persist within the distal 
oviduct for up to 47 weeks, whereas other segments of the female reproductive tract 
in the mouse seem to be characterized by a considerably higher turnover. Notably, LT-
LCRs do not express CD44, estrogen and progesterone receptors, and, in confirmation 
of their quiescent nature, ki67.
Figure 2. Characterization of identified LT-LRCs (12 week chase) in mouse distal oviduct. immunofluorescent 
double-labeling was performed for GfP and ERα (A), GfP and PR (B), GfP and Ki67 (C), GfP and CD44 (D) 
and CD44 and ERα (E). DAPi staining was performed to display all cell nuclei. White arrowheads indicate 
Ki67 positive cells, the yellow arrowhead indicates a cell which is positive for CD44 as well as GfP. 
486
Figure 3. isolated LT-LRC can form self-renewing spheroids in culture. Oviducts from 12 week chased mice 
were dissected and a single cell suspension was analyzed by fACS (A). from three different 12 week chased 
mice, GfP+ and GfP-negative (GfP-) cells were isolated by fACSorting and cultured in Matrigel under serum-
free conditions to assay their capacity to form spheroids. furthermore, when spheroids were formed self-
renewal was assayed as indicated in the Materials and Methods section (B). Using limiting dilutions, individual 
GfP+ cells were cultured for 0 to 20 days in Matrigel under serum-free conditions, thus forming a polarized 
epithelial organoid (C).  The bars in C represent 50 μM.
Ex-vivo isolated long-term LRCs can form epithelial spheroids 
When cultured in serum free and in 3D conditions (e.g. matrigel), stem cells are able to 
form organoid structures often referred to as spheroids. in order to provide indication 
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of the presence of stem-like cells among the LT-LRCs isolated ex-vivo from the distal 
oviduct, we fACSorted GfP+ and GfP-negative cells from the oviducts of  12-week chased 
animals (figure 3A). Sorted single cells were subsequently cultured in Matrigel under 
serum-free conditions to assay their capacity to form spheroids. As shown in figure 3B, 
GfP+ cells form spheroids at a significantly higher rate (1 spheroid/150 cells) than GfP-
negative cells (1 spheroid/>7000 cells). Next, enzymatic and mechanic dissociation of 
the primary organoids was applied in order to obtain a single cell suspension   to plate 
in matrigel and serum-free culture conditions. Secondary spheroids were exclusively 
obtained from the primary spheroids derived from GfP+ cells though not from those 
obtained from GfP-negative cells. Likewise, tertiary spheroids were readily obtained 
from the secondary organoids (fig. 3B).
Next, we followed single LT-LRCs during the spheroid-formation process. Using 
limiting dilutions, individual GfP+ cells were first recognized and observed to divide and 
progressively form an unstructured organoid (between day 2 and 5; fig. 3C). Over the 
course of the next few days (day 6-20), early organoids kept growing, simultaneously 
forming a polarized epithelial-like outer layer of the spheroid (fig. 3C). 
in the female reproductive tract, epithelial cells are, amongst others, characterized 
by cytoplasmic cytokeratin 8 (CK8) and membrane β-catenin expression. hence, 
both the mouse distal oviduct and whole spheroids were analyzed for these markers. 
As shown in the supplementary figure 5 the staining pattern in the distal oviduct 
sections (Supplementary fig. 5A and 5C) and in the spheroids (Supplementary fig. 
5B and 5D) was similar, confirming the epithelial nature of the LRC-derived organoids 
(Supplementary fig. 5).  
Under serum-free conditions, spheroids continue to grow slowly but steadily 
and maintain an undifferentiated appearance for at least 10 weeks. however, upon 
exposure to serum-supplemented (10% fCS) medium, cell morphology undergoes 
dramatic modifications (fig. 4). in order to facilitate the visualization of cell morphology 
during the differentiation process, spheroids were cultured in the presence of 
doxycycline and followed by using confocal  and phase contrast microscopy and 3D 
image reconstruction (fig. 4 and Supplementary Movie 1). Already one day after serum 
exposure, the formation of multiple cell layers was observed (fig. 4B and 4C). At day two, 
monolayers of organoid-derived cells were observed to spread out of spheroids which 
came in contact with the plastic surface of the culture dish spread (fig. 4D and 4E). 
furthermore, an additional small hollow structure appeared to bud out of the 
differentiating organoids (fig. 4D). At day 3, the budded structure appeared as a hollow 
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tube occasionally flanked by secondary budding structures (fig. 4f). Subsequently, cells 
continued to divide, as shown by loss of GfP signaling (after doxycycline withdrawal 
from the culture medium), with tube elongation proceeding (fig. 4G). When, in 
independent experiments, spheroids were allowed to differentiate for 9 (fig. 4h) and 
20 days (fig. 4i) respectively, formation of more complex structures was observed.
Figure 4. Differentiation of spheroids. 20 day old spheroids derived from oviducts of 12 week chased mice 
were pulsed for one day with doxycycline and were subsequently allowed to differentiated for 0 (A), 1 (B and C), 
2 (D and E), 3 (f) or 6 days (G) in the presence of 10% fCS. The two columns of images on the left hand side of 
the figure represent confocal images taken at two different planes (bottom and middle). The phase-contrast 
images in the third colum from the left represents a detail from the confocal image. C represents a spheroid 
derived from a different animal which was induced to differentiate for 1 day, displaying formation of multiple 
cell layers as indicated by nuclear DAPi staining and immunofluorescence for CK8. in E attachment of the 
spheroid to the culture dish is shown. h and i represent spheroids isolated from different animals that were 
allowed to differentiate for 9 days (h) and for 20 days (i) showing complex structures (nuclei were stained 
with hoechst 34580).
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Figure 5. Differentiation of spheroids towards specific cell lineages of the female reproductive tract. Early 
spheroids (2 days of culture, A), late spheroids (2 weeks of culture, B) and spheroids which were stimulated 
to differentiated (10% fCS added to the culture medium for 2 days, C) were stained for ERα, CD44, PR and 
PAEP expression and compared to stained sections from mice distal oviduct (D), proximal oviduct (E) and 
endometrium (f). The red arrows indicate ERα positive cells, the black arrows indicate ERα negative cells.  
in summary, LT-LRCs isolated ex-vivo from the distal oviduct can form undifferentiated, 
self-renewing spheroids which, upon differentiation induction, are able to give rise to 
complex epithelial structures. 
To assess the capacity of the LT-LRC-derived organoids to differentiate towards 
specific cell lineages of the female reproductive tract, early (1 or 2 days culture), late 
(2 weeks culture), and more differentiated (see above) spheroids were analyzed by ihC 
and compared with histological sections from the distal and proximal oviduct, and from 
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the endometrium for ERα, CD44, PR and PAEP (progestagen-associated endometrial 
protein, also referred to as glycodelin A) expression (fig. 5). Whereas in early spheroids 
all cells were ERα, CD44, PR and PAEP negative (fig. 5A), late spheroids showed a 
distinct expression pattern with increased ERα and CD44 expression (though ERα 
negative cells could still be recognized; fig. 5B, black arrow). PR and PAEP expression 
was negative (fig. 5B). Upon staining of the distal oviduct for the same markers (fig. 5D) 
it was observed that the expression pattern of distal oviduct overlapped with that of 
the late spheroids. further induction of spheroid differentiation resulted in most cells 
expressing ERα, PR, CD44, and the uterine marker PAEP (fig. 5C). Notably, comparison 
of the expression data between differentiated spheroids and the proximal oviduct and 
endometrium (fig. 5E and 5f) revealed marked similarities.
hence, upon differentiation of spheroids arisen from LT-LRCs, they acquire 
expression characteristic of cell lineages of the proximal oviduct and endometrium. 
DiSCUSSiON
in this study we employed a h2B-GfP label-retaining assay to identify and isolate 
quiescent, stem-like cells from the mouse female reproductive tract. Notably, most of 
the LT-LRCs were observed to cluster within the distal oviduct (including the fimbrial 
region) where they persist for up to 1 year. in the endometrium, however, only very 
few and isolated epithelial and stromal LRCs were observed. Previously, by following 
an analogous approach though based on BrdU labeling, Chan and colleagues also 
observed a very small population of LRCs in the luminal endometrial epithelium 
and in the adjacent stroma after an 8-12 weeks chase18. As far as the endometrium is 
concerned, the results presented here are largely in agreement with those by Chan et al. 
(Supplementary fig. 1), although in our pulse-chase analysis the glandular epithelium 
appeared to loose its label at a slower rate than the luminal epithelium, in contrast with 
the data obtained from BrdU-labeled mice18 (Supplementary fig. 1B and 1C). As for 
the distal oviduct (including the fimbrial region), where a striking number of LRCs was 
observed to cluster, it was never previously reported as a niche of quiescent cells with 
stem cell properties. LRCs from this compartment persisted for as long as one year and 
possibly longer (more extensive chase time-points were not reviewed). 
interestingly, during embryonal development of the Müllerian duct, the anterior 
region of the coelomic cavity, where Lim1+ mesoepithelial cells are induced to 
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invaginate by Wnt4 expressing cells from the Wolffian duct, gives rise in a later stage to 
the distal oviduct. This initial invagination elongates alongside the Wolffian duct under 
the influence of Wnt9b27, 28 and a population of rapidly proliferating progenitor cells at 
the tip of the elongation is responsible for the outgrowth which will eventually form 
the Müllerian ducts29, 30. At birth, maturation of the Müllerian duct proceeds with the 
single layered epithelium differentiating into a stratified squamous epithelium of the 
anterior vagina and cervix, a simple columnar epithelium of the uterus, and a ciliated 
or secretory epithelium of the oviducts. Subsequently, mesenchymal cells in close 
proximity to the epithelial cells differentiate to form stromal cells, while more distant 
mesenchymal cells differentiate into smooth muscle thus forming the outer muscle 
layer of the adult Müllerian duct. The last step in female genital tract development is 
the formation of the glands of the uterus by budding from the luminal epithelium into 
the uterine stroma followed by extensive branching and coiling.
To characterize the identity of the LT-LRCs in the distal oviduct, fACSorting was 
employed to prospectively isolate and culture them under conditions which favor 
outgrowth of self-renewing organoids from clonogenic stem cells. in contrast with 
h2B-GfP-negative cells, only LRCs were able to generate spheroids in matrigel, serum-
free cultures. Moreover, LT-LRC-derived organoids were shown to differentiate in 
the presence of 10% fCS leading to epithelial cell polarization and the formation of 
complex, multi-layered structures. ihC analysis of different organoid stadia of the in vitro 
differentiation process revealed that, while early spheroids (2 days of culture) did not 
express any of the selected endometrium- and oviduct-specific markers in agreement 
with their stem-like potential (fig. 5), later stages of spheroid growth (2 weeks in culture) 
displayed ER and CD44 expression similar to the levels of these distal oviduct markers 
in vivo. Notably, spheroids induced to further differentiate readily displayed expression 
of all differentiation markers including those specific for the proximal oviduct and 
endometrium. hence, our results indicate that the LT-LRCs localized in the distal end of 
the oviduct are capable of differentiation towards several epithelial lineages of distinct 
segments of the female reproductive tract in the mouse.
The finding of quiescent, stem-like cells in the distal female reproductive tract 
(Műllerian duct) could also be relevant for the ongoing discussion on the origin of 
ovarian cancer 31-33. in short, there are good indications that some ovarian cancer 
subtypes do not originate from ovarian surface epithelial cells, but from cells in the 
distal oviduct. The following observations seem to corroborate this hypothesis: (i) 
reviewing prophylactically removed adnexa from women with a BRCA1/2 mutation 
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showed a high incidence of serous tubal intraepithelial carcinomas in the distal 
oviduct and fimbriae34-36. (ii) The three most prevalent ovarian cancer subtypes are 
morphologically strongly reminiscent of different Müllerian duct structures (serous 
ovarian cancer bears likeness to epithelium of the distal oviduct; endometrioid ovarian 
cancer shows similarity to endometrial glands; and mucinous ovarian cancer resembles 
the endocervical epithelium37). (iii) Well-established ovarian cancer biomarkers such as 
CA12538, hE439 and PAx240, are proteins expressed by endometrial and tubal epithelial 
cells though not in OSE38-40. in view of our findings, an admittedly speculative though 
stimulating hypothesis can be formulated. Repeated physical and biochemical 
(inflammatory cytokines and reactive oxygen species present during ovulation) insults 
may trigger cell cycle entrance and expansion in the otherwise quiescent LT-LRCs 
in the distal oviduct. Because of the alleged expansion of the LT-LCR compartment 
upon tissue injury and their differentiation potential, these cells may represent, upon 
specific (epi)genetic alterations, the cell of origin of distinct ovarian cancer subtypes. 
Moreover, these cells may also be involved in the development of endometrial benign 
and malignant aberrations such as endometrial hyperplasia, endometriosis and 
endometrial cancer.
in summary, we show that quiescent cells located in the distal oviduct (including 
the fimbrial region) have stem-like properties and can differentiate into distinct cell 
lineages specific of endometrium, proximal and distal oviduct. future lineage-tracing 
studies will be needed to elucidate the role played by these cells in homeostasis, tissue 
injury and cancer of the female reproductive tract in the mouse and eventually in man. 
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Supplementary Figure 1. Pulse-chase experiment using the doxycycline-inducible h2B-GfP system focusing 
on the endometrium. Detection of GfP using a fluorescent microscope is shown in A. Details show a strong 
GfP signal in epithelial cells and a weaker signal in stromal and myometrial cells. immunohistochemistry for 
GfP (B+C) was used to detect LRCs in the luminal epithelium (B), or glandular epithelium and stroma (C) in 
pulsed mice (0 weeks, 0w), and in mice chased for 1 (1w), 2 (2w), 4 (4w), 8 (8w) and 12 weeks. Black arrows 
point to LRCs in the glandular epithelium at 2 weeks and in the stroma at 4 and 8 weeks. 
494
Supplementary Figure 2. Pulse-chase experiment using the doxycycline-inducible h2B-GfP system focusing 
on GfP signaling in the entire female reproductive tract. After treatment with doxycycline this mouse was 
chased for 12 weeks before sacrifice. Staining was performed for GfP and in A, a low magnification overview 
of uterus, oviduct and ovary is shown. Details are shown in B (LT-LRCs in fimbrial region of the distal oviduct), 
c (proximal oviduct) and D (endometrium). 
Supplementary Figure 3. Progesterone receptor expression in the female reproductive tract of a 12 week 
chased animal. Staining was performed for PR and in A, a low magnification overview of uterus, oviduct 
and ovary is shown. Details are shown in B (fimbrial region of the distal oviduct), c (proximal oviduct) and D 
(endometrium). 
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Supplementary Figure 4. Ki67 staining in the fimbrial region of the distal oviduct (A) and a developing 
ovarian follicle (B). Yellow arrows indicate rare dividing cells in the fimbrial region of the distal oviduct. 
Rapidly dividing granulose cells of a developing ovarian follicle are used as a positive control for staining.
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Supplementary Figure 5. Expression of epithelial markers β-catenin (A and B) and cytokeratin 8 (CK8, C 
and D) in the fimbrial region of the distal oviduct (A and C) and in early spheroids (B and D). Oviducts from 
12 week chased mice were dissected for immunohistochemistry and for single cell digestion. The single cell 
digest was fACSorted for GfP+ cells, which were allowed to form spheroids for 5 days. Two markers, β-catenin 
(B, green) and CK8 (D, green), were used to stain complete spheroids. The nuclei were contra-stained with 
DRAQ5 (red). The fluorescent images were captured using confocal microscopy.
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in this thesis, i describe our investigations to assess mechanisms involved in 
development and homeostasis of female reproductive organs. The research was 
focussed on molecular and cellular events affecting development and maintenance of 
Müllerian duct derived organs. At a molecular level, a role for Wnt/β-catenin signaling 
in maintaining mouse uterine integrity (Chapter 2), and involvement of Wnt/β-catenin 
signaling in normal and aberrant hormone signaling in the human endometrium 
(Chapter 3) were demonstrated. At a cellular level, we were able to identify a 
population of quiescent, stem-like cells located in the mouse distal oviduct (Chapter 4). 
We anticipate that these new findings, together with other recent observations from 
us and others, will help to advance basic and clinical research into three important 
disorders of the female reproductive system: endometrial cancer, endometriosis and 
ovarian cancer.
Wnt/β-catenin signaling in uterine development
As indicated in the introduction of this thesis, Wnt/β-catenin signaling affects the 
uterus both during early embryogenesis and during adult life. for example, Wnt ligands 
Wnt4 and Wnt9b are important for embryonal outgrowth of the Müllerian ducts1,2, and 
Wnt5a and Wnt7a are involved in correct patterning of the Müllerian ducts into upper 
part of the vagina, the cervix, uterus and oviducts. in the adult, Wnt/β-catenin signaling 
has a central function in maintenance of a fine balance between proliferation (Wnt/β-
catenin signaling has been turned on) and differentiation (Wnt/β-catenin signaling has 
been turned off). 
Constitutive activation of Wnt/β-catenin signaling has been associated with the 
development of endometrial cancer3,4. Over 30% of human endometrial cancers show 
nuclear β-catenin staining5,6 which is the hallmark for activation of Wnt/β-catenin 
signaling. Activation of Wnt/β-catenin signaling can be caused by gene mutations7 
found in components of the degradation complex consisting of APC, AxiN, β-catenin, 
CK1 and GSK3β. for example, defective APC expression caused by loss of heterozygozity8, 
promoter hypermethylation8, or truncation mutations9 will prevent formation of the 
degradation complex which will prohibit degradation of β-catenin, allowing it to travel 
to the nucleus. here, nuclear β-catenin will displace the transcription repressor Groucho 
(TLE), allowing members of the TCf/LEf transcription factor family to modulate the 
expression of Wnt/β-catenin signaling downstream target genes such as cyclin D1, IGF1 
and CD4410,11.
To further clarify the role of constitutive activation of Wnt/β-catenin signaling 
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during early Müllerian duct development, we generated a novel mouse model in 
which the Apc gene was conditionaly recombined in mesenchymal cells surrounding 
the developing Müllerian duct by breeding Amhr2Cre/+ mice12 with Apc15lox/15lox mice13. 
The rationale behind affecting surrounding mesenchymal cells was that these cells are 
important in regulating early development of the Müllerian duct through a paracrine 
mechanism14. 
in order to confirm Wnt/β-catenin signaling activation in vivo in our mice, a number of 
control experiments were conducted. By using an Amhr2-LacZ reporter mouse model it 
was shown that the promoter of Amhr2 was mainly active in myometrial cells. This finding 
was further confirmed by breeding Amhr2Cre mice with the Rosa26 reporter (R26R)15 
to review Cre expression. in these mice also fairly weak and irregular galactosidase 
expression was shown in the myometrium. Next, using laser capture microdissection, 
recombination of the Apc15lox allele in Amhr2Cre/+;Apc15lox/15lox mice was confirmed in the 
myometrial areas of the uterus. interestingly, stromal cells, which are thought to arise 
from the mesenchymal cells surrounding the embryonal Müllerian duct, did not stain 
for galactosidase activity in the two reporter mice models, nor did these cells display 
recombination in Amhr2Cre/+;Apc15lox/15lox mice. it is interesting to know where these adult 
stromal cells come from, or which cells are the developmental predecessors of adult 
endometrial stoma cells. Arango et al. (2008) showed in one of their figures that not all 
cells surrounding Müllerian duct display Amhr2 promoter activity16. The stromal cells in 
adult uterus may originate from these cells. Also, epithelial to mesenchymal transition 
is a common process during embryogenesis17, but whether Müllerian duct cells could 
lose their polarity and be converted into a more mesenchymal phenotype, thus giving 
rise to uterine stromal cells which do not express Amhr2, remains to be seen.
The most pronounced phenotype for adult Amhr2Cre/+;Apc15lox/15lox mice is 
disorganisation or even loss of myometrial muscle fibres, a finding which was 
confirmed in PgrCre/+;Apc15lox/15lox animals. This seems to indicate that Apc knockout does 
affect development of myometrium. interestingly, Tanwar et al. (2009) also observed 
ectopic endometrial tissue within the myometrium of Amhr2Cre/+;Ctnnb1f(Ex3)/+ animals18 
and refers to this as resembling a human condition known as adenomyosis (which 
is characterized by glandular tissue present within the myometrial layer). A question 
which arises is whether movement of endometrial cells into the myometrium is an 
active process or passive displacement of tissue to a site where muscular cells have died. 
According to our results described in Chapter 2, loss of integrity of the myometrium 
seems to allow for passive movement of endometrial tissue into the muscle layer rather 
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than that the presence of endometrial cells signifies active invasion.
Recently, Tanwar et al. (2011)19 published a manuscript dealing with the effects of 
Wnt/β-catenin signaling in the uterus. interestingly, the mouse model used by Tanwar 
et al. (2011) was very comparable to the model used by us20. Tanwar et al. (2011) used 
Amhr2Cre to drive recombination of Apc by deletion of exon 14, while in our mice 
the larger exon 15 of Apc was deleted 20. Similar to our strategy, Tanwar et al. (2011) 
reviewed activity of Cre by breeding Amhr2Cre mice with LacZ and Yfp reporter mice. 
Using these reporter mice they could show Amhr2 driven Cre activity in the endometrial 
stroma; unfortunately they do not mention or show the myometrium. This is in contrast 
to our observations descripted in Chapter 2 and the observations documented by the 
original authors of the Amhr2-Cre model16. it is possible that the mixed background of 
the mice which were used by Tanwar et al.19 lies at the basis of this profound difference 
(C57BL/6;129/SvEv mixed genetic background). Effects of genetic background on 
tumorigenesis have been reported in p53-deficient mice21. The phenotype of the 
animals used by Tanwar et al. (2011) partly resembles the phenotype described in our 
study in Chapter 2 which reported myometrial defects and invasion of endometrial 
tissue into the myometrium, but Tanwar’s (2011) model also shows endometrial cancer, 
a phenotype which was not observed by us. 
Sex hormones and Wnt/β-catenin signaling pathway
The female sex hormones estradiol and progesterone are important in controlling 
the cyclical renewal of the endometrium. in the first half of a regular menstrual 
cycle, the proliferative phase, estradiol is required to expand the endometrial layer 
by inducing cell proliferation, while in the second half of the menstrual cycle, the 
secretory phase, progesterone levels rise, which antagonizes estradiol’s proliferative 
activity and induces differentiation of the endometrium22. furthermore, increased 
estrogen signaling and decreased progesterone signaling are both risk factors for 
endometrial hyperplasia and cancer23-25. for this reason, progesterone, i.e. the synthetic 
medroxyprogesterone acetate (MPA), has been employed in the treatment of advanced 
and recurrent endometrial cancer (response-rates 15-25%)26, and in the treatment of 
well-differentiated endometrial carcinoma in pre-menopausal women that want to 
preserve fertility (response-rates 60%)27,28. 
Wnt/β-catenin signaling has also been implicated in regulation of the normal 
menstrual cycle29,30. Nuclear β-catenin staining, for example, was observed during the 
proliferative phase but disappears during the secretory phase of the menstrual cycle31. 
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furthermore, Cloke et al. (2008)32 showed that knockdown of the progesterone receptor 
resulted in activation of Wnt/β-catenin signaling in differentiating human endometrial 
stromal cells. in agreement with this, Satterfield (2008)33 could show that progestagens, 
when administered to pregnant sheep, induced a transient decline in Wnt/β-catenin 
signaling activity. it has also been reported that over 30% of well-differentiated estrogen-
associated tumors (Type i endometrioid) show nuclear β-catenin accumulation5,8. 
Moreover, hou et al. (2004)34 confirmed that estrogen-induced uterine growth was 
effectively interfered by the Wnt/β-catenin inhibitor SfRP2 and Jeong et al. (2009)35 
showed that sex hormones could not induce a decidual reaction when β-catenin was 
dominantly stabilized or conditionally ablated. 
Based on these observations, we investigated the hypothesis that progesterone 
counteracts the proliferative effects of estradiol during the normal menstrual cycle, 
during hyperplasia and during early endometrial carcinogenesis, by inhibiting Wnt/β-
catenin signaling, as described in Chapter 3. According to this hypothesis, sex hormones 
may modulate Wnt/β-catenin signaling to maintain the balance between proliferation 
and differentiation.
By comparing gene expression profiles between control, E2 and E2+MPA treated 
patients36, a significant number of targets and components of the Wnt/β-catenin 
signaling pathway were found differentially regulated in the hormone-treated 
endometrium. Notably, the Wnt/β-catenin signal inhibitor DKK1 and the alleged 
inhibitor fOxO1 were highly induced by E2 in combination with MPA treatment. This 
possibly indicates that in the secretory phase of the menstrual cycle, progesterone 
inhibits Wnt/β-catenin signaling via induction of expression of DKK1 and fOxO1. in 
literature, it has been reported that DKK1 inhibits Wnt/β-catenin signaling by binding 
to the Wnt co-receptors LRP5 and LRP637, while fOxO1 binds directly to β-catenin38 
thus sequestering the molecule from its normal nuclear activities39. 
By using the well differentiated endometrial cancer cell line ishikawa, we could 
show that progesterone up-regulated DKK1 and fOxO1 protein expression, which is in 
agreement with the gene expression profiles showing that both genes are up-regulated 
among the E2+MPA treated patients or during the secretory phase of the menstrual 
cycle and30. furthermore, it was also shown that progesterone effectively inhibited 
Wnt/β-catenin reporter activity.  Moreover, upon DKK1 and fOxO1 knock-down (alone 
or in combination) by the use of lentiviral sequence-specific shRNAs, inhibition of Wnt/
β-catenin signaling by progesterone treatment was partly circumvented. 
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in summary, we have provided mechanistic evidence of a crosslink between the 
actions of sex hormones and Wnt/β-catenin signaling in the endometrium. The Wnt/β-
catenin signaling inhibitors DKK1 and fOxO1 are two key molecules involved in the 
process. Our results provide support for the hypothesis that during the proliferative 
phase of the menstrual cycle increased estradiol levels induce Wnt/β-catenin signaling 
leading to enhancement of proliferation, while during the secretory phase progesterone 
levels inhibit Wnt/β-catenin signaling thereby counterbalancing estradiol-induced 
proliferation and enhancing differentiation.
Stem cells in the female reproductive tract
Stem cells are relatively undifferentiated and naïve cells which have the ability to self-
renew and differentiate into progenitor cells of essentially all cell lineages. Adult stem 
cells for tissues like the skin40-43, mammary gland44, stomach45,46 and the hematopoietic 
system47,48 have been identified, but current knowledge on stem cells in the female 
reproductive tract is limited49. 
A clonogenicity experiment using human endometrial epithelial cells 50 brought the 
first evidence that endometrial stem cells did exist in the human uterus. in this thesis, 
we employed a non-mutagenic and cell cycle independent approach, namely in vivo 
pulse-chase with h2B-GfP, to identify and isolate quiescent, long-term label-retaining 
stem-like cells (LT-LRCs) from the mouse female reproductive tract. This animal model 
is an inducible model, in which h2B-GfP is induced when doxycyclin is added to the 
drinking water. it was observed that LT-LRCs clustered in the distal oviduct. interestingly, 
this distal region is also the region where during embryogenesis the initial Müllerian 
duct anlagen appear, and subsequently, a population of rapidly proliferating progenitor 
cells is induced to invaginate and the structure elongates alongside the Wolffian duct, 
eventually to form the Müllerian duct51,52. 
To characterize these newly identified LT-LRCs in the distal oviduct, a double 
immunofluorescence staining analysis was performed for expression of ERα, PRA/B, 
CD44 and Ki67. The most significant finding was that in a region which was virtually 
devoid of PRA/B it was specifically the LT-LRCs which were also negative for ERα. These 
observations seem to indicate that the LT-LRCs are resistant to sex hormone signaling. 
for the mammary gland, the presence of ERα and PRA/B negative stem cells has also 
been reported53-55. Notably, although the mammary stem cells were ERα-negative they 
did respond very well to estrogen signaling. Asselin-Labat et al. (2010)54 show that 
ovariectomy reduces the number of mammary stem cells while in mice treated with 
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oestrogen plus progesterone or in pregnant mice their numbers markedly increase. 
These authors argue that ERα positive cells in close vicinity of the ERα negative 
mammary stem cells, upon hormonal stimulation, produce a paracrine factor called 
RANKL which can bind to its receptor RANK at the surface of ERα negative mammary 
stem cells. Treatment of mice with anti RANKL monoclonal antibody indeed impaired 
clonogenicity of the mammary stem cells. in our study, we did observe that ERα positive 
cells were situated next to the ERα negative LT-LRCs. it is, however, not clear whether 
the above-mentioned paracrine mechanism is involved in the interaction between the 
LT-LRCs in the distal oviduct and their ERα positive neighbours.
in order to investigate putative stemness of our LT-LRCs, these cells were isolated by 
flow cytometry on basis of high retention of h2B-GfP in the nucleus, and cultured under 
serum-free conditions in matrigel. in contrast to isolated cells which did not express 
GfP, the LT-LRCs formed undifferentiated structures which are called spheroids. The 
epithelial origin of spheroids was confirmed by the expression of markers such as CK8 
and membranous β-catenin56-59. furthermore, upon digestion of spheroids, individual 
cells were able to form new spheroids, which, upon repeated digestion again formed 
new spheroids. This experiment indicates that LT-LRCs have the capacity to self-renew. 
The most interesting experiment, however, was when spheroids were kept in culture for 
a longer period of time and were then allowed to differentiate. During the initial weeks 
of culture it was noted that next to ERα negative cells, ERα-positive cells appeared, and 
CD44 expression increased over time. This condition seems to resemble the situation 
in the distal oviduct where ERα/CD44 negative cells (LT-LRCs) reside next to ERα/CD44 
positive cells. As depicted in figure 1, it is hypothesized that these newly produced 
ERα/CD44-positive cells could function as progenitor cells for different structures of 
the female reproductive tract. What argues in favour of this hypothesis is that oviduct, 
uterus, cervix and part of the vagina all develop from the same embryonal structure: 
the Müllerian duct. furthermore, as already indicated, embryonal development starts 
at in the region that later forms the distal oviduct. What argues against this hypothesis 
is maybe the distance which progenitor cells need to travel before being able to 
populate the proximal oviduct and endometrium, although one could also argue that 
if the fertilized oocyte can travel from distal oviduct to the uterus, this might also be 
possible for an epithelial progenitor cell which is shedded from the distal oviduct. 
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Figure 1. Schematic representation of a hypothesis for epithelial cell lineages formed from LT-LRCs in the 
distal oviduct. The different cell types are represented in different colors and their specific marker composition 
is indicated. The LRCs at distal oviduct, proximal oviduct and uterus are shown.
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After serum-stimulation, the structure of the spheroids changed dramatically and 
many cells became positive for ERα, PRA/B and CD44. furthermore, when we stained 
for the endometrial differentiation marker PAEP, expression of this marker was also 
markedly enhanced, indicating similarity between differentiated spheroids and 
proximal oviduct and endometrium. 
On the basis of data obtained so far it is hypothesized that LT-LRCs located in 
the distal oviduct are stem cells for the epithelial lining of the proximal oviduct and 
endometrium. 
Based on the remarkable location of these cells, the present observations are possibly 
also of relevance for cancer and in particular ovarian cancer. A prevailing hypothesis on 
the origin of ovarian cancer argues that ovarian surface epithelial cells (OSEs) become 
damaged by physical (repeated ovulation) and biochemical insults (inflammatory 
cytokines and reactive oxygen species present during ovulation). The damaged OSEs 
may over time become trapped into the ovarian cortical stroma thus forming cortical 
inclusion cysts. Due to exposure to a new hormone rich environment, epithelial cells 
lining these cysts undergo metaplasia and eventually progress into dysplasia and 
ovarian carcinogenesis60. interestingly, endometriosis is also often recognized as a 
condition predisposing to the formation of ovarian cysts, indicating that Müllerian 
duct derivatives can become trapped in the ovarian cortical stroma61-63 and give rise to 
intra-ovarian endometriosis. however, as far as ovarian cancer is concerned, different 
observations indicate that, apart from the OSEs, cells originating from the Müllerian duct 
may be involved64-66. first, reviewing prophylactically removed adnexa from women 
with a BRCA1/2 mutation, several authors showed a high incidence of serous tubal 
intraepithelial carcinomas in the distal oviduct67-69. in sporadic serous ovarian cancer, 
tubal intraepithelial carcinoma of the distal oviduct and fimbriae was observed in 50% 
of the cases70, while in extraovarian peritoneal carcinoma (otherwise indistinguishable 
from serous ovarian cancer), no involvement of OSEs could be demonstrated. Second, 
the three most prevalent ovarian cancer subtypes are morphologically strongly 
reminiscent of different Müllerian duct structures: serous ovarian cancer bears likeness 
to epithelium of the distal oviduct (the fimbriae); endometrioid ovarian cancer 
shows similarity to endometrial glands; and mucinous ovarian cancer resembles the 
endocervical epithelium65. Third, well-established ovarian cancer biomarkers such 
as CA12571, hE472 and PAx273, are proteins expressed by both endometrial and tubal 
epithelial cells but not in OSEs71-73. fourth, in patients with a p53 mutation, the distal 
oviduct is found as a common site of origin for early serous carcinogenesis74-76. p53 is 
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known to play an important role in maintaining quiescence in hematopoietic stem cells77 
and to control symmetric vs. asymmetric cell division in mammary stem cells78,79. 
in view of our present findings, we would like to propose a new hypothesis on 
the origin of ovarian cancer. The above-mentioned repeated physical (ovulation) and 
biochemical (inflammatory cytokines and reactive oxygen species present during 
ovulation) insults may trigger cell cycle entrance and expansion in the otherwise 
quiescent LT-LRCs in the distal oviduct. Because of the alleged expansion of the LT-
LCRs compartment upon tissue injury and their differentiation potential, these cells 
may represent the cells of origin of distinct aberrations. Before or after undergoing 
subsequent genetic or epigenetic alterations, the aberrations could affect different 
derivatives of the reproductive tract, such as giving rise to endometriosis, early 
malignant precursors of serous ovarian cancer and possibly other ovarian cancer 
subtypes.
in conclusion, the quiescent cells identified in the distal oviduct are likely to 
represent bona fide stem cells. future lineage-tracing experiments should be addressed 
to further reveal the role of the LT-LRCs.
Concluding remarks and future perspectives
The overall theme of the present thesis has been to investigate and identify signaling 
pathways and stem cells in the mammalian female reproductive system. With 
the observation that activation of Wnt/β-catenin signaling in mesenchymal cells 
surrounding the Müllerian ducts induced profound myometrial defects, and with the 
identification of DKK1 and fOxO1 as intermediates of progesterone induced inhibition 
of Wnt/β-catenin signaling, a central role for Wnt/β-catenin signaling in regulation 
of uterine homeostasis was established. This work is currently being continued by 
studying cross-talk between the actions of sex hormones and Wnt/β-catenin signaling 
in endometrial carcinogenesis. 
The study into the identification of quiescent, stem-like cells in the mouse distal 
female reproductive tract should be considered as a starting point. Much more work is 
needed before we can be certain that these stem-like cells in the distal oviduct are stem 
cells of most epithelial derivatives of the Müllerian ducts. Lineage tracing experiments 
in which we can visualize that cells originating from the distal oviduct can populate 
the proximal oviduct and endometrium are vital to proof this point. furthermore, 
more clinical studies in which the link between aberrations in the distal oviduct and 
endometriosis and ovarian cancer is made are currently being conducted. 
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During her fertile years, the endometrium of fertile women undergoes regular cycles 
of regeneration, differentiation and shedding, driven by changing concentrations of 
the steroid hormones estradiol and progesterone. in the present study, the role of 
Wnt/β-catenin signaling in relation to steroid hormone signaling and the balance 
between proliferation and differentiation was investigated. furthermore, since the 
consequence of hormone signaling in the endometrium is tissue degradation followed 
by regeneration, the role of stem cells was also investigated.
Chapter 1, the introductory chapter, reviews what is known about a functional 
link between steroid hormone signaling, Wnt/β-catenin signaling, and endometrial 
physiology. in the normal human menstrual cycle, estradiol induces proliferation during 
the first two weeks, whereas during the third and fourth week of the cycle progesterone 
inhibits this estradiol-induced proliferation thus stimulating cellular differentiation. The 
two steroid hormones also play a role in oncogenesis of the endometrium: unbalanced 
hormone signaling can induce endometrial hyperplasia which may continue to develop 
into endometrial cancer. Elevated estrogen receptor signaling, caused for example by 
overweight or use of the synthetic analog tamoxifen, significantly increases the risk of 
endometrial carcinogenesis. 
The role of Wnt signaling in initiation, development and function of the female 
reproductive tract, investigated, in particular in the mouse, is significant. There are 
good indications that hormonal regulation of the human menstrual cycle during 
reproductive life is also mediated by estrogen-induced activation and progesterone-
induced inhibition of Wnt/β-catenin signaling. Similar to elevated estradiol signaling, 
constitutive activation of canonical Wnt signaling has been associated with the 
development of human endometrial cancer. Activation of Wnt/β-catenin signaling 
can be caused by mutations that affect β-catenin degradation, in women and in 
mouse models. These mutations result in β-catenin protein stabilization which, upon 
translocation to the nucleus, can activate transcription of Wnt/β-catenin target genes. 
Chapter 2 describes the role of constitutive activation of Wnt/β-catenin signaling 
during uterine development using a novel mouse model (Amhr2Cre/+;Apc15lox/15lox). 
it was observed that the promoter of Amhr2 was mainly active in myometrial cells. 
furthermore, PCR results confirmed that recombination of the Apc15lox allele occurred 
exclusively in the myometrial region of the uterus. Consequently, the main phenotype 
in these Apc conditional knock-down mice was loss and aberrant organization of the 
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myometrial muscle fibers. As a result, endometrial tissue was sometimes observed 
in the myometrial layer, a phenomenon which in our opinion is a passive rather than 
an active invasion process. A mouse model to inactivate Wnt/β-catenin signaling 
specifically in the epithelial cells of the developing Mϋllerian ducts, unfortunately is 
not available. hence, we cannot exclude that there might be an additional role for this 
signaling pathway, directly targeting the epithelial cells and their derivatives. 
As described in Chapter 3, it was investigated how progesterone regulates Wnt/β-
catenin signaling. Among the genes regulated by progesterone in patients, DKK1 and 
FOXO1 as well as genes encoding other known inhibitors of Wnt/β-catenin signaling, 
were identified and selected for further investigations. first, it was established that 
during progesterone-driven inhibition of Wnt/β-catenin signaling, both DKK1 and 
FOXO1 gene expression were induced. Secondly, it was observed that progesterone 
could not inhibit Wnt/β-catenin signaling in the endometrial cancer cell lines in the 
absence of DKK1 and fOxO1 (by the use of lentiviral sequence-specific shRNAs). To 
put the observed results in a clinical perspective, patient samples (hormone treated 
endometria, hyperplasia and endometrial cancers) were evaluated for Wnt signaling 
activation using a histochemical approach. On the basis of these results it was concluded 
that the Wnt inhibitory effect of progesterone action is likely to play a rate-limiting 
role in the maintenance of endometrial homeostasis and, upon loss of progesterone 
signaling, in tumor onset and progression towards malignancy.
in Chapter 4, the research focused on the identification, characterization and 
isolation of stem cells of the female reproductive tract is presented. The initial 
observations were well in line with those published in several papers by the group of 
Gargett et al. (2004, 2006, 2009), where they reported short-term label-retaining cells 
in the uterus. in subsequent experiments, we found a new population of long-term 
label-retaining cells at the distal oviduct. These cells were isolated and were shown 
to be able to form undifferentiated spheroids in stem cell medium, to self-renew 
upon re-culture of spheroid cells, and to differentiate into glandular structures which 
expressed markers of mature Műllerian epithelial cells. Based on these findings, it is 
suggested that these quiescent, stem-like cells located within the distal oviduct might 
contribute to the homeostasis of at least part of the female genital tract, in particular 
concerning the cyclic regeneration of the epithelial lining of the endometrium and the 
maintenance of the oviduct. 
Chapter 5 provides a general discussion, where the significance of the current 
findings is put into a broader perspective. 
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SAMENvATTiNG 
Tijdens de vruchtbare jaren van een vrouw ondergaat haar endometrium, onder invloed 
van wisselende concentraties van de steroïdhormonen oestradiol en progesteron, 
regelmatige cycli van opbouw, differentiatie en afbraak. in het onderzoek beschreven 
in dit proefschrift werd de rol van Wnt/β-catenine signalering in relatie tot hormonale 
regulatie van de balans tussen opbouw (proliferatie van cellen) en differentiatie van 
het endometrium-weefsel onderzocht. Daarnaast werd, omdat hormoonwerking in 
het endometrium leidt tot een cyclus van weefsel-afbraak gevolgd door opbouw, de 
rol van stamcellen bestudeerd.
Hoofdstuk 1, de algemene introductie, beschrijft de functionele relatie tussen 
steroïdhormoon-signalering, Wnt/β-catenine-signalering en endometrium fysiologie. 
in de eerste twee weken van een normale menstruele cyclus zorgt oestradiol voor 
proliferatie van het endometrium. in de derde en vierde week wordt deze oestradiol-
geïnduceerde proliferatie vervolgens geremd door progesteron, wat leidt tot stimulatie 
van cellulaire differentiatie. Daarnaast spelen zowel oestradiol als progesteron een 
rol in de oncogenese van het endometrium waarbij afwijkende hormoonsignalering 
kan leiden tot endometriumhyperplasie, welke zich soms kan ontwikkelen tot 
endometriumkanker. verder leidt een verhoogde oestradiol receptor-signalering, 
bijvoorbeeld veroorzaakt door overgewicht of het gebruik van Tamoxifen, tot een 
significant verhoogd risico op endometriumkanker. 
De rol van Wnt/β-catenine signalering tijdens de ontwikkeling en functie van het 
vrouwelijk genitaal (voornamelijk onderzocht in muizen) is zeer groot. in muizen, 
alsmede in de humane situatie, zijn er goede aanwijzingen dat de cyclus tijdens de 
vruchtbare periode gereguleerd wordt door oestradiol-geïnduceerde activering en 
progesteron-geïnduceerde remming van Wnt/β-catenine signalering. Continue Wnt/
β-catenine-signalering is, evenals verhoogde oestradiol-signalering, geassocieerd 
met het ontstaan van humaan endometrium-carcinoom. in muismodellen en ook 
in mensen, kan activering van Wnt/β-catenine signalering worden veroorzaakt door 
mutaties in β-catenine. Deze mutaties leiden tot stabilisatie van het β-catenine 
eiwit, dat, na translocatie naar de celkern, zorgt voor transcriptie van Wnt/β-catenine 
gereguleerde genen. 
Hoofdstuk 2  beschrijft de rol van continue Wnt/β-catenine signalering tijdens de 
ontwikkeling van de uterus in een nieuw muismodel (Amhr2Cre/+; Apc15lox/15lox), waarmee 
het mogelijk is om vanaf embryonale dag 12.5 het Apc gen (adenomatosis polyposis coli) 
uit te schakelen, en daarmee Wnt/β-catenine signalering aan te zetten.  in dit model werd 
gevonden dat de promotor van het Amhr2 gen voornamelijk actief was in de cellen van 
het myometrium. verder bevestigde analyse van de hoeveelheid aanwezig mRNA (met 
de PCR methode) dat recombinatie van het Apc15lox allel exclusief plaatsvond in het 
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myometrium van de uterus. Als gevolg hiervan ontwikkelden deze Apc mutant muizen 
een fenotype gekenmerkt door verlies van myometriumweefsel en een afwijkende 
structuur van het myometrium. hierdoor werd soms endometriumweefsel in het 
myometrium waargenomen, waarschijnlijk ten gevolge van passieve invasie. Echter, 
omdat een inactiverend Wnt/β-catenine muismodel specifiek voor epitheelcellen van 
de ontwikkelende Müllerse gang niet beschikbaar is, kunnen we een rol voor Wnt/β-
catenine signalering in deze cellen niet uitsluiten. 
in Hoofdstuk 3 werd onderzocht hoe progesteron Wnt/β-catenine-signalering 
reguleert. Tussen een groot aantal progesteron-gereguleerde genen in het humane 
endometrium werden de Wnt/β-catenine-signalering-remmende genen DKK1 en 
FOXO1 geïdentificeerd en vervolgens gebruikt in verder onderzoek. Ten eerste werd 
bewezen dat tijdens progesteron-geinduceerde remming van Wnt/β-catenine-
signalering DKK1 en FOXO1 tot expressie werden gebracht. Daarnaast werd gevonden 
dat remming van Wnt/β-catenine-signalering door progesteron niet mogelijk was 
in endometriumkanker-cellijnen waarin DKK1 en FOXO1 afwezig waren (met behulp 
van sequentie-specifieke lentivirale shRNAs). Om deze gevonden resultaten klinisch 
te bevestigen werden vervolgens weefsels van patiënten (met hormoon behandeld 
endometrium, met endometrium hyperplasie of met endometriumkanker) gebruikt 
voor immunohistochemische analyse van de activiteit van Wnt/β-catenine-signalering. 
Naar aanleiding van deze resultaten werd geconcludeerd dat remming van Wnt/β-
catenine-signalering door progesteron een remmende rol speelt in de endometrium-
homeostase en dat verlies van progesteron-signalering kan leiden tot maligne 
ontaarding van het endometrium.
Hoofdstuk 4 beschrijft de identificatie, karakterisering en isolatie van stamcel-
achtige cellen van de vrouwelijke geslachtsgangen. De eerste bevindingen bevestigden 
eerder werk van Gargett et al. (2004, 2006 en 2009) waarin “label-retaining” cellen 
van de uterus werden gevonden. Daarnaast werd een nieuwe populatie van zeer 
lang aanwezig blijvende “label-retaining” cellen geïdentificeerd in de distale oviduct. 
Deze cellen werden geïsoleerd en bleken in staat om, in speciaal stamcel-medium, 
ongedifferentieerde spheroïden te vormen, te regenereren en te differentiëren in 
epitheliale klierachtige structuren met morfologische kenmerken van de Müllerse 
gangen, waaruit uterus en oviduct tijdens de embryonale ontwikkeling ontstaan. Op 
basis van deze bevindingen werd gehypothetiseerd dat deze, in de distale oviduct 
gelokaliseerde, stamcel-achtige cellen bijdragen aan de homeostase van tenminste 
een deel van de vrouwelijke geslachtsgangen. 
Hoofdstuk 5 is een algemene beschouwing waarin de gevonden resultaten en de 
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General academic skills 
Laboratory animal science  2007 3 ECTS
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• Lentivirus making and RNAi  30 hours
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• From development to disease 2007 1 ECTS
• Biomedical research techniques VI 2007 1 week
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• 1st Erasmus Flow day 2009 8 hours
• InDesign course 2011 0.2 ECTS
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• 1st “Stem Cells, Development and Regulation”, Amsterdam 2007 16 hours
• Annual presentation at Josephine Nefkens Institute (JNI), Rotterdam (oral) 2008 40 hours
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 2009 40 hours
• The 2nd Dutch stem cells meeting, Rotterdam 2009 10 hours
• 13th Molecular Medicine Day, Rotterdam (oral) 2009 45 hours
• Leiden International Medical Student Conference, Leiden (oral) 2009 25 hours
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MMP7 matrix metallopeptidase 7
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